As filed with the Securities and Exchange Commission on October 10, 2014
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
AGENUS INC.
(Exact name
of Registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
2836 |
|
06-1562417 |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
3 Forbes Road
Lexington, MA 02421
(781) 674-4400
(Address,
including zip code, and telephone number, including area code, of Registrants principal executive offices)
Garo H. Armen
Chief Executive Officer and Chairman of the Board
Agenus Inc.
3 Forbes
Road
Lexington, MA 02421
(781) 674-4400
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copy to:
Gerald E. Quirk, Esq.
Choate, Hall & Stewart LLP
Two International Place
Boston, MA 02110
(617)
248-5000
Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.
If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box. ¨
If any of the securities being registered on this form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the Securities Act), other than securities offered only in connection with dividend or interest reinvestment plans, check the
following box. x
If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, please check the following box. ¨
If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, please check the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer |
|
¨ |
|
Accelerated filer |
|
x |
Non-accelerated filer |
|
¨ (Do not check if a smaller reporting company) |
|
Smaller reporting company |
|
¨ |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Each Class of
Securities to be Registered(1) |
|
Amount
to be
Registered |
|
Proposed
Maximum Offering
Price Per Share |
|
Proposed
Maximum Aggregate
Offering Price(2) |
|
Amount of
Registration Fee(6) |
Common Stock, $0.01 par value per share (3) |
|
(4) |
|
(4) |
|
(4) |
|
(4) |
Preferred Stock, $0.01 par value per share |
|
(4) |
|
(4) |
|
(4) |
|
(4) |
Warrants |
|
(4) |
|
(4) |
|
(4) |
|
(4) |
Debt Securities |
|
(4) |
|
(4) |
|
(4) |
|
(4) |
Total: (5) |
|
|
|
|
|
$150,000,000 |
|
$17,430.00 |
|
|
(1) |
There are being registered hereunder such indeterminate number of shares of common stock, such indeterminate number of shares of preferred stock, such indeterminate principal amount of debt securities and such
indeterminate number of warrants to purchase common stock, preferred stock or debt securities, as will have an aggregate initial offering price not to exceed $150,000,000. If any debt securities are issued at an original issue discount, then the
issue price, and not the principal amount, of such debt securities shall be used for purposes of calculating the aggregate initial offering price of all securities issued. Any securities registered under this Registration Statement may be sold
separately or as units with other securities registered hereunder. The securities registered hereunder also include such indeterminate amounts and numbers of shares of common stock and numbers of shares of preferred stock, and principal amounts of
debt securities, as may be issued upon conversion of or exchange for preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the anti-dilution provisions of any such securities.
|
(2) |
The proposed maximum per unit and aggregate offering prices per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered
under this Registration Statement. |
(3) |
The aggregate amount of common stock registered under this Registration Statement is limited, with respect to at the market offerings, to that which is permissible under Rule 415(a)(4) under the
Securities Act. |
(4) |
Not required to be included in accordance with General Instruction II.D. of Form S-3. |
(5) |
Estimated solely for purposes of determining the registration fee pursuant to Rule 457(o) under the Securities Act. |
(6) |
Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this Registration Statement include unsold securities previously registered by the registrant on the registrants
Registration Statement (File No. 333-185657), filed on December 21, 2012, as amended by Amendment No. 1 to Form S-3 filed on January 7, 2013, and declared effective on January 10, 2013 (the Prior Registration
Statement). The Prior Registration Statement registered, among other things, the offer and sale of an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities, and an
indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities (collectively, the Shelf Securities) having an aggregate initial offering price not to exceed $150,000,000, $61,851,961 of which Shelf
Securities remain unsold as the date of filing of this Registration Statement. The Registrant has determined to include in this Registration Statement unsold Shelf Securities under the Prior Registration Statement having an aggregate offering price
of $61,851,961 (the Unsold Securities). Pursuant to Rule 415(a)(6) under the Securities Act, the filing fee of $8,436.61 relating to the Unsold Securities under the Prior Registration Statement, which was paid or was deemed to have been
paid under the Prior Registration Statement, will continue to be applied to the Unsold Securities registered pursuant to this Registration Statement. The Registrant is also registering new securities on this registration statement with an aggregate
initial offering price of $88,148,039 (the New Securities), which aggregate offering price is not specified as to each class of security (see footnote (1)). A filing fee of $8,993.39 with respect to the New Securities is being paid in
connection with the filing of this Registration Statement. To the extent that, after the filing date hereof and prior to the effectiveness of this Registration Statement, the Registrant sells any Unsold Securities pursuant to the Prior Registration
Statement, the Registrant will identify in a pre-effective amendment to this Registration Statement the updated amount of Unsold Securities from the Prior Registration Statement to be included in this Registration Statement pursuant to Rule
415(a)(6) and the updated amount of New Securities to be registered on this Registration Statement. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of the Unsold Securities under the Prior Registration Statement will be deemed
terminated as of the date of effectiveness of this Registration Statement. |
The Registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) of the Securities Act, may determine.
EXPLANATORY NOTE
This registration statement contains two prospectuses, one of which includes securities that the registrant has previously registered under a
Form S-3 registration statement that we filed on December 21, 2012, as amended by Amendment No. 1 to Form S-3 filed on January 7, 2013 (the Prior Registration Statement), as follows:
|
|
|
a base prospectus which covers the offering, issuance and sale of up to $150,000,000 of common stock, preferred stock, warrants, debt securities and units of the registrant, which includes $61,851,961 of common stock,
preferred stock, warrants, debt securities and units of the registrant that were registered in the Prior Registration Statement; and |
|
|
|
a Sales Agreement prospectus covering the offering, issuance and sale of up to 10,000,000 shares of the registrants common stock that may be issued and sold under an At Market Issuance Sales Agreement dated
October 10, 2014 between the registrant and MLV & Co. LLC (the Sales Agreement). |
Upon
effectiveness of this Registration Statement, it is intended that any primary offering of unsold securities by the registrant under the Prior Registration Statement will be terminated. The Prior Registration Statement will remain in effect, however,
for secondary offerings of the registrants securities by selling stockholders pursuant to prospectuses filed as part of the Prior Registration Statement.
The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base
prospectus will be specified in a prospectus supplement to the base prospectus. The Sales Agreement prospectus immediately follows the base prospectus. The common stock that may be offered, issued and sold under the Sales Agreement prospectus is
included in the $150,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the Sales Agreement, any portion of the 10,000,000 shares included in the Sales Agreement prospectus
that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.
The information contained in this prospectus is not complete and may be changed. A
registration statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This
prospectus is not an offer to sell these securities, and is not soliciting an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction where such offer, solicitation or sale is not permitted or would be
unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Subject To Completion, Dated October 10, 2014
PROSPECTUS
$150,000,000
of
Common Stock
Preferred Stock
Warrants
Debt Securities
Units
We may offer to
sell to the public, from time to time in one or more offerings for an aggregate initial offering price of up to $150,000,000:
|
|
|
shares of our common stock; |
|
|
|
shares of our preferred stock; |
|
|
|
warrants to purchase shares of our common stock, preferred stock and/or debt securities; |
|
|
|
debt securities consisting of debentures, notes, or other evidences of indebtedness; or |
|
|
|
units consisting of any combination of the foregoing securities. |
We may offer and sell any
combination of the securities in amounts, at prices and on terms that we will determine at the time of any particular offering, to or through one or more agents, dealers or underwriters, or directly to purchasers, including through subscription
rights offerings, on a continuous or delayed basis. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement.
This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will
provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information
contained in this document. You should read this prospectus and any applicable prospectus supplement before you invest.
Our common stock
is listed on The NASDAQ Capital Market and trades under the symbol AGEN. On October 8, 2014, the last sale price of our common stock as reported on the NASDAQ Capital Market was $2.81 per share. The other securities that may be
offered are not listed on any securities exchange or included in any automated quotation system.
Investing in
our securities involves risks. See Risk Factors on page 4 of this prospectus.
Neither the
Securities and Exchange Commission, nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is
, 2014.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the SEC), using a
shelf registration process for the delayed offering and sale of securities pursuant to Rule 415 under the Securities Act of 1933, as amended (the Securities Act). Under the shelf process, we may, from time to time, sell
any of the Securities described in this prospectus in one or more offerings for an aggregate initial offering price of up to $150,000,000.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide one or
more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and the
accompanying prospectus supplement together with the additional information described under the heading Where You Can Find More Information beginning on page 40 of this prospectus.
We have not authorized anyone to provide you with any additional information. This prospectus and any accompanying prospectus supplement do
not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any
circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is
accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates.
As used in this prospectus, unless the context otherwise requires, the terms we, us, our, the
Company and Agenus mean, collectively, Agenus Inc. and its subsidiaries and their predecessors.
- 1 -
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference in this prospectus the information we file with the SEC. This helps us disclose
certain important information to you by referring you to the documents we file. The information we incorporate by reference is an important part of this prospectus. Because we are incorporating by reference future filings with the SEC, this
prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to
determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. We incorporate by reference each of the documents listed below.
|
|
|
our Annual Report on Form 10-K for the year ended December 31, 2013 (File No. 000-29089); |
|
|
|
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 (File No. 000-29089); |
|
|
|
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 (File No. 000-29089); |
|
|
|
our Current Reports on Form 8-K filed on July 24, 2014, July 1, 2014, June 30, 2014, June 27, 2014, June 16, 2014, April 28, 2014, April 25,
2014, April 2, 2014, March 20, 2014, March 5, 2014, February 21, 2014, February 13, 2014 (as amended by our Current Report on Form 8-K/A filed on April 29, 2014), February 6,
2014, February 4, 2014, January 21, 2014, January 14, 2014 and January 13, 2014 (except, with respect to each of the foregoing, for portions of such reports which were deemed to be furnished and not filed) (File
No. 000-29089); |
|
|
|
our Proxy Statement on Schedule 14A filed with the SEC on March 10, 2014 (File No. 000-29089); and |
|
|
|
the description of our common stock contained in our registration statement on Form 8-A filed under the Securities Exchange Act of 1934, as amended (the Exchange Act) on January 24, 2000, including any
amendment or reports filed for the purpose of updating such descriptions (File No. 000-29089). |
All filings by Agenus
pursuant to the Exchange Act subsequent to the date hereof and prior to effectiveness of this registration statement are incorporated in this registration statement and deemed to be a part hereof from the date of filing of such documents or reports.
In addition, all documents and reports filed by Agenus subsequent to the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities
offered have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents or reports. Any statement
contained in a document incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated by reference herein modifies
or supersedes such statement. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to
these filings. You should review the complete document to evaluate these statements.
You may obtain copies of these documents, other than
exhibits, free of charge on the Companys website, www.agenusbio.com, as soon as reasonably practicable after they have been filed with the SEC and through the SECs website, www.sec.gov.
- 2 -
CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS
This prospectus, any prospectus supplement, and any information incorporated by reference into this prospectus or prospectus supplement may
contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. You can identify these forward-looking statements by the fact they use words such
as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will,
potential, opportunity, future and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking
statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or
change any of them, and could cause actual outcomes to differ materially from current expectations. These statements are likely to relate to, among other things, our business strategy, our research and development, our product development efforts,
our ability to commercialize our product candidates, the activities of our licensees, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty
regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations and intentions.
Although the Company believes it has been prudent in its plans and assumptions, no assurance can be given that any goal or plan set forth in
forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. The Company undertakes no obligation to release publicly any revisions to forward-looking
statements as a result of new information, future events or otherwise.
Retrocyte
Display® and Stimulon® are registered trademarks of Agenus Inc. and its subsidiaries. All rights reserved.
- 3 -
RISK FACTORS
Before purchasing any of the securities you should carefully consider the risk factors relating to Agenus incorporated by reference in this
prospectus from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms 10-K, 10-Q and 8-K and in the other documents
incorporated by reference in this prospectus. For a description of these reports and documents, and information about where you can find them, see Where You Can Find More Information and Incorporation of Certain Documents By
Reference. Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects.
- 4 -
THE COMPANY
Agenus Inc. (including its subsidiaries, also referred to as Agenus, the Company, we, us, and
our) is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein (HSP)-based vaccines and adjuvants. We are focused on immunotherapeutic products based on our core
platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. We assess the development, commercialization
and/or partnering strategies with respect to each of our internal product candidates periodically based on several factors, including clinical trial results, competitive positioning, and funding requirements and resources.
Our Retrocyte Display® technology platform and CPM antibody programs became part of
our portfolio with the acquisition of 4-Antibody AG (4-AB), a European-based biopharmaceutical company, in February 2014. The Retrocyte Display® technology platform is intended to
enable, among other things, the rapid generation and optimization of fully-human and humanized monoclonal antibodies against a broad range of target antigens of interest. We currently have six pre-clinical CPM antibody programs, which target GITR,
OX40, CTLA-4, PD-1, TIM-3 and LAG-3. Although we envision using Retrocyte Display® to drive the discovery of future CPM antibody candidates, not all candidates will necessarily be derived from
the use of this technology. For example, our current antibody candidates targeting GITR were derived independently of Retrocyte Display®. We have selected product candidates targeting GITR
(agonists) and CTLA-4 (antagonists) to advance into investigational new drug applications (INDs) enabling development. In addition, we plan to identify development candidates for the other four CPM antibody programs within the next six
months, in order to be in a position to file INDs on at least four candidates within the next two years. During the quarter ended June 30, 2014, we entered into a collaboration and license agreement with Merck to discover and optimize
fully-human antibodies against two undisclosed cancer targets using the Retrocyte Display®. Under this agreement, Merck will be responsible for the clinical development and commercialization
of antibodies generated under the collaboration, and we are eligible to receive approximately $100 million in potential payments associated with the completion of certain clinical, regulatory and commercial milestones, as well as royalty payments on
worldwide product sales. We are exploring other potential partnering opportunities for our Retrocyte Display® technology platform and CPM antibody programs.
Our Prophage Series cancer vaccines are based on our HSP technology platform. Our Prophage Series vaccines are autologous therapies derived
from cells extracted from the patients tumor. As a result, Prophage Series vaccines contain a precise antigenic fingerprint of a patients particular cancer and are designed to reprogram the bodys immune system to target
only cells bearing this fingerprint, reducing the risk that powerful anti-cancer agents will target healthy tissue and cause debilitating side effects often associated with chemotherapy and radiation therapy. We believe that in contrast to many
other autologous vaccines that are based on cellular preparations, the Prophage Series vaccines are based on a stable protein preparation produced by a less complex manufacturing process. Our Prophage Series vaccines are currently being studied in
two different settings of glioblastoma multiforme, or GBM: newly diagnosed and recurrent disease. In July 2014, we announced final results from a single-arm, open-label Phase 2 trial showing that patients with newly-diagnosed glioblastoma who
received the Prophage vaccine in addition to the standard of care had a survival benefit over patients who received standard of care alone.
Also within our HSP technology platform is HerpV, a recombinant, synthetic vaccine containing multiple antigens derived from the herpes
simplex 2 virus. Combining our HSP technology and our QS-21 Stimulon® adjuvant, HerpV represents a potential new approach to the treatment of genital herpes. In November 2013, we released top
line results from a Phase 2, randomized, double blind, multicenter clinical trial of HerpV in HSV-2 positive genital herpes patients, which showed that the trial met its primary endpoint. In June 2014, we announced that the majority of patients
showed an immune response to the HSV antigens after a series of vaccinations and a booster dose at six months. More than half of those vaccinated developed a robust anti-HSV cytotoxic T-cell immune response, and in those patients there was a
statistically significant reduction in viral load, which is believed to be relevant in the reduction of transmission and symptoms. After the booster shot,
- 5 -
HerpV demonstrated a durable reduction in viral shedding approximating 14%, and remains consistent with the reduction in viral shedding observed during the initial treatment period. HerpV evokes
immune responses to the mix of HSV2 peptides contained in the vaccine in a substantial majority of patients. We believe that this is the first demonstration of a correlation between immune response and a statistically significant reduction in viral
load. We are currently seeking a partner for the further development of our HerpV program. Notwithstanding these data, it is uncertain whether the degree of benefit conferred by HerpV will be sufficient to (i) warrant additional clinical trials
funded by us or (ii) attract a development partner.
Our QS-21 Stimulon®
vaccine adjuvant is a saponin extracted from the bark of the Quillaja saponaria tree, an evergreen tree native to warm temperate central Chile. QS-21 Stimulon has become a key component in the development of investigational preventive vaccine
formulations across a wide variety of infectious diseases and, investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been studied in approximately 50,000 patients. Our QS-21 Stimulon is
extensively partnered with GlaxoSmithKline (GSK) and JANSSEN Alzheimer Immunotherapy (JANSSEN AI) and includes several vaccine candidates in Phase 2 and Phase 3 clinical trials. In July 2014, GSK submitted to the European
Medicines Agency an application for marketing approval of its malaria vaccine candidate incorporating QS-21 Stimulon. If any of our partners products containing QS-21 Stimulon successfully complete clinical development and receive approval for
commercial sale, we are generally entitled to receive milestone payments as well as royalties for 10 years after commercial launch, with some exceptions.
In addition to our internal development efforts, we continue to pursue collaborative, out-licensing and/or partnering opportunities for our
portfolio programs and product candidates, as well as explore in-licensing, acquisitions and collaborative arrangements in areas of synergy with our existing programs. Our business activities have included product research and development,
intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development, business development, and support of our collaborations.
We have financed our operations primarily through the sale of equity and debt securities. We believe that, based on our current plans and
activities, our working capital resources at June 30, 2014, plus potential proceeds from our existing license, supply, and collaborative agreements, will be sufficient to satisfy our liquidity requirements through the first half of 2015. We
expect to attempt to raise additional funds in advance of depleting our current funds. We may attempt to raise funds by: (1) pursuing collaborative, out-licensing and/or partnering opportunities for our portfolio programs and product candidates
with one or more third parties, (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing and/or (5) selling equity securities. Satisfying long-term liquidity needs may require the
successful commercialization and/or substantial out-licensing or partnering arrangements for our Retrocyte Display® technology platform, CPM antibody programs, HerpV and the Prophage Series
vaccines, and vaccines containing QS-21 Stimulon under development by our licensees. Our long term success will also be dependent on the successful identification, development and commercialization of potential other product candidates, each of
which will require additional capital with no certainty of timing or probability of success. If we incur operating losses for longer than we expect and/or we are unable to raise additional capital, we may become insolvent and be unable to continue
our operations.
You can find more information about us in our filings with the Securities and Exchange Commission referenced in the
sections in this document titled Incorporation of Certain Documents by Reference and Where You Can Find More Information beginning on pages 2 and 40, respectively.
- 6 -
USE OF PROCEEDS
This prospectus relates to the securities that may be offered and sold from time to time by us. We expect to use the net proceeds from the
sale of the securities from offerings under this prospectus for general corporate purposes unless the applicable prospectus supplement states otherwise. General corporate purposes may include working capital, capital expenditures, repayment and
refinancing of debt, research and development expenditures, clinical trial expenditures, acquisitions of additional companies or technologies and investments. We may temporarily invest the net proceeds in investment-grade, interest-bearing
securities until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds.
- 7 -
RATIO OF EARNINGS TO FIXED CHARGES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Years Ended December 31, |
|
|
|
June 30, 2014 |
|
|
2013 |
|
|
2012 |
|
|
2011 |
|
|
2010 |
|
|
2009 |
|
Ratio of Earnings to Fixed Charges |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of Earnings to Cover Fixed Charges |
|
$ |
(8,399 |
) |
|
$ |
(30,073 |
) |
|
$ |
(11,325 |
) |
|
$ |
(23,276 |
) |
|
$ |
(21,906 |
) |
|
$ |
(30,318 |
) |
Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of Earnings to Cover Combined Fixed Charges and Preferred Stock Dividends |
|
$ |
(8,501 |
) |
|
$ |
(33,233 |
) |
|
$ |
(12,117 |
) |
|
$ |
(24,066 |
) |
|
$ |
(22,696 |
) |
|
$ |
(31,108 |
) |
For purposes of the ratio of earnings to fixed charges and the ration of combined fixed charges and preferred
stock dividends to earnings, earnings consist of income before income taxes, interest and the portions of rentals representative of the interest factor. Fixed charges consist of interest expense and the portions of rentals
representative of the interest factor.
- 8 -
DILUTION
If there is a material dilution of the investors equity interest from the sale of common equity securities offered under this
prospectus, we will set forth in any prospectus supplement the following information regarding any such material dilution of the equity interests of purchasers purchasing securities in an offering under this prospectus:
|
|
|
the net tangible book value per share of our equity securities before and after the offering; |
|
|
|
the amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers in the offering; and |
|
|
|
the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers. |
- 9 -
DESCRIPTION OF SECURITIES
The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the material
terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so
indicate in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We will also include in the prospectus supplement information, where applicable, about material U.S. federal income tax
considerations relating to the securities, and the securities exchange, if any, on which the securities will be listed.
We may sell from
time to time common stock, preferred stock, debt securities, warrants to purchase any such securities or any combination of the foregoing.
In this prospectus, we refer to the common stock, preferred stock, debt securities and warrants to be sold by us collectively as
securities. The total dollar amount of all securities that we may issue under the registration statement of which this prospectus forms a part will not exceed $150,000,000.
If we issue debt securities at a discount from their original stated principal amount, then we will use the issue price, and not the principal
amount, of such debt securities for purposes of calculating the total dollar amount of all securities issued under this prospectus.
This
prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.
- 10 -
DESCRIPTION OF CAPITAL STOCK
Agenus is authorized to issue up to 140,000,000 shares of common stock, par value $0.01 per share, with 62,684,465 shares issued as of
September 30, 2014. Agenus is also authorized to issue up to 5,000,000 shares of preferred stock, par value $0.01 per share, with 31,620 Series A-1 convertible preferred stock issued as of September 30, 2014.
The following description of the Agenus capital stock does not purport to be complete and is qualified in all respects by reference to
Agenus restated certificate of incorporation and bylaws, and the Delaware General Corporation Law (the DGCL).
- 11 -
DESCRIPTION OF COMMON STOCK
General
Each share of Agenus
common stock has the same relative rights and is identical in all respects with each other share of common stock.
Voting Rights
Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of common stock
are entitled to receive dividends out of assets legally available for payment of dividends, as the board may from time to time determine. Each stockholder is entitled to one vote for each share of common stock held on all matters submitted to a vote
of stockholders. Our certificate of incorporation does not provide for cumulative voting for the election of directors, which means that the holders of a majority of the shares voted can elect all of the directors then standing for election. The
common stock is not entitled to preemptive rights and is not subject to conversion or redemption. Each outstanding share of common stock offered by this prospectus will, when issued, be fully paid and nonassessable.
Dividends
Holders of common stock are
entitled to share ratably in any dividends declared by our board of directors, subject to any preferential dividend rights of any outstanding preferred stock. Dividends consisting of shares of common stock may be paid to holders of shares of common
stock. We have never declared or paid cash dividends on our common stock. We do not intend to pay cash dividends in the foreseeable future.
Preemptive
Rights
Holders of common stock do not have any preemptive rights with respect to any shares that may be issued by Agenus in the
future. Thus, Agenus may sell shares of its common stock without first offering them to the then holders of common stock.
Liquidation
In the event of any liquidation or dissolution of Agenus, whether voluntary or involuntary, the holders of Agenus common stock would be
entitled to receive pro rata, after payment of all debts and liabilities of Agenus, all assets of Agenus available for distribution, subject to the rights of the holders of any preferred stock which may be issued with a priority in liquidation or
dissolution over the holders of common stock.
Listing
Our common stock is listed on The NASDAQ Capital Market under the symbol AGEN. On October 8, 2014, the last reported sale
price for our common stock on The NASDAQ Capital Market was $2.81 per share. As of October 6, 2014, we had approximately 1,382 stockholders of record.
Anti-Takeover Provisions
Statutory Business
Combination Provision
Delaware has adopted a business combination statute (Section 203 of the DGCL) that may also have
additional anti-takeover effects to provisions in Agenus restated certificate of incorporation and bylaws. Section 203 of the DGCL, which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any business
combination with an interested stockholder for a period of three years following the time that such stockholder became an interested stockholder, unless:
|
|
|
the board of directors of the corporation approves either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder, prior to the time the interested stockholder
attained that status; |
- 12 -
|
|
|
upon the closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding, for purposes of determining the number of shares outstanding, those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
|
|
|
at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at
least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
With certain exceptions, an
interested stockholder is a person or group who or which owns 15% or more of the corporations outstanding voting stock (including any rights to acquire stock pursuant to an option, warrant, agreement, arrangement or understanding,
or upon the exercise of conversion or exchange rights, and stock with respect to which the person has voting rights only), or is an affiliate or associate of the corporation and was the owner of 15% or more of such voting stock at any time within
the previous three years.
In general, Section 203 defines a business combination to include:
|
|
|
any merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
|
|
|
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; |
|
|
|
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
|
|
|
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
A Delaware corporation may opt out of this provision with an express provision in its original certificate of incorporation or an
express provision in its amended and restated certificate of incorporation or bylaws resulting from a stockholders amendment approved by at least a majority of the outstanding voting shares. However, Agenus has not opted out of
this provision. Section 203 could prohibit or delay mergers or other takeover or change-in-control attempts and, accordingly, may discourage attempts to acquire Agenus.
Size of the Board and Vacancies
Our
bylaws provide that the exact number of directors is determined by resolution of the board of directors or by the stockholders at the annual meeting. Our board of directors has the right to fill any vacancies resulting from death, resignation,
disqualification or removal, as well as any newly created directorships arising from an increase in the size of the board.
Amendment of Charter
Provisions
The affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our voting
stock, voting together as a single class, is required to, among other things, amend, alter, change or repeal certain provisions of our restated certificate of incorporation. Our bylaws may only be amended (or new bylaws adopted) by the board of
directors or the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our voting stock represented in person or by proxy at the meeting at which the amendment is voted on.
- 13 -
Undesignated Preferred Stock
We could issue preferred stock that could have other rights, including economic rights senior to our common stock, so that the issuance of the
preferred stock could adversely affect the market value of our common stock. The issuance of the preferred stock may also have the effect of delaying, deferring or preventing a change in control of Agenus without any action by the stockholders. The
effects of issuing preferred stock could include one or more of the following:
|
|
|
restricting dividends on the common stock; |
|
|
|
diluting the voting power of the common stock; |
|
|
|
impairing the liquidation rights of the common stock; or |
|
|
|
discouraging, delaying or preventing changes in control or management of Agenus. |
Transfer Agent
The transfer agent and registrar for Agenus common stock is American Stock Transfer & Trust Company. Its telephone number is
(800) 937-5449.
- 14 -
DESCRIPTION OF PREFERRED STOCK
We currently have authorized 5,000,000 shares of preferred stock, of which 31,620 shares have been designated as series A-1 convertible
preferred stock, 10,000 shares have been designated as series B1 convertible preferred stock, and 5,250 have been designated as series B2 convertible preferred stock. As of the date of this prospectus, all of the series A-1 convertible preferred
stock is issued and outstanding in the amount described in the preceding sentence. As of the date of this prospectus, none of the shares of Series B1 convertible preferred stock or Series B2 convertible preferred stock are issued or outstanding. The
remaining 4,953,130 authorized shares of preferred stock are undesignated and not issued or outstanding as of the date of this prospectus. As of the date of this prospectus, we do not have any equity securities that would be senior to, or on par
with, our authorized preferred stock.
Series A Preferred Stock
On September 24, 2003, we sold 31,620 shares of series A convertible preferred stock, par value $.01 per share, which we refer to as
series A preferred stock. Under the terms and conditions of the Certificate of Designation creating the series A preferred stock, the stock is convertible by the holder at any time into shares of our common stock, is non-voting, carries
a 2.5 percent annual dividend yield, has an initial conversion price of $94.86, and is redeemable by us at its face amount on or after September 24, 2013. In February 2013, we entered into a Securities Exchange Agreement with the holder of our
series A preferred stock pursuant to which the holder exchanged all 31,620 of the then outstanding shares of our series A preferred stock for an equivalent number of shares of series A-1 convertible preferred stock (series A-1 preferred
stock). The terms of the series A-1 preferred stock are materially identical to the series A preferred stock, except that shares of the series A-1 preferred stock accrue a 0.63% annual dividend, as compared to a 2.5% annual dividend for the
series A preferred stock. After giving effect to the transaction, no shares of the series A preferred stock remain outstanding. The liquidation value of the series A-1 preferred stock is equal to $1,000 per share outstanding plus any accrued and
unpaid dividends. The Certificate of Designation does not restrict the repurchase or redemption of shares by us while there is an arrearage in the payment of dividends. The Certificate of Designation does not contemplate a sinking fund. This
description of the series A-1 preferred stock is qualified in its entirety by reference to the Certificate of Designation.
Series B Preferred Stock
On September 10, 2007, we issued 10,000 shares of our series B1 convertible preferred stock and 5,250 shares of our series B2
convertible preferred stock (the series B1 convertible preferred stock and the series B2 convertible preferred stock are referred to collectively as the class B convertible preferred stock) to a single institutional investor. In April
2008, all of the series B1 convertible preferred stock was converted into 264,199 shares of our common stock via a cashless conversion. Shares of the series B2 convertible preferred stock permitted the investor to purchase common shares for
consideration of up to 35 percent of the total dollar amount previously invested pursuant to an agreement with the investor, including conversions of the series B1 convertible preferred stock, at a purchase price equal to the lesser of $24.96 per
common share or a price calculated based on the then-prevailing price of our common stock. The total number of shares of common stock that were issuable to the holder of the class B convertible preferred stock could not have exceeded 19.9% of our
outstanding common stock. In April 2009, we issued 988,202 shares of our common stock upon conversion of 2,145 shares of our series B2 convertible preferred stock via cashless conversions. No dividends were paid on the class B convertible preferred
stock and there are no liquidation preferences. In September 2014, all issued and outstanding shares of Series B2 convertible preferred stock were cancelled and extinguished in accordance with the Certificate of Designation. This description of the
class B convertible preferred stock is qualified in its entirety by reference to the Certificate of Designation.
Undesignated Preferred Stock
This section describes the general terms and provisions of the preferred stock that we may offer by this prospectus. The prospectus supplement
will describe the specific terms of the series of the preferred stock offered
- 15 -
through that prospectus supplement. Those terms may differ from the terms discussed below. Any series of preferred stock we will issue will be governed by our restated certificate of
incorporation, as amended, including the certificate of designations relating to such series of preferred stock, and our bylaws, as amended. In this section entitled Description of Preferred Stock, references to Agenus,
we, our and us refer only to Agenus Inc. and not to its consolidated subsidiaries.
We will fix the
rights, preferences, privileges and restrictions of the preferred stock of each series in the certificate of designations relating to that series. We will incorporate by reference as an exhibit to the registration statement that includes this
prospectus the form of any certificate of designations which describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. This description will include the following, to the
extent applicable:
|
|
|
the title and stated value; |
|
|
|
the number of shares we are offering; |
|
|
|
the liquidation preference per share; |
|
|
|
the dividend rate, period and payment date, and method of calculation for dividends, if any; |
|
|
|
whether any dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; |
|
|
|
the provisions for a sinking fund, if any; |
|
|
|
the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; |
|
|
|
any listing of the preferred stock on any securities exchange or market; |
|
|
|
whether the preferred stock will be convertible into our common stock and, if applicable, the conversion price, or how it will be calculated, and the conversion period; |
|
|
|
whether the preferred stock will be exchangeable into debt securities and, if applicable, the exchange price, or how it will be calculated, and the exchange period; |
|
|
|
voting rights, if any, of the preferred stock; |
|
|
|
preemptive rights, if any; |
|
|
|
restrictions on transfer, sale or other assignment, if any; |
|
|
|
whether interests in the preferred stock will be represented by depositary shares; |
|
|
|
a discussion of any material or special United States federal income tax considerations applicable to the preferred stock; |
|
|
|
the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; any limitations on issuance of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and |
|
|
|
any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. |
When we issue shares of preferred stock under this prospectus, the shares, when issued in accordance with the terms of the applicable
agreement, will be validly issued, fully paid and non-assessable and will not have, or be subject to, any preemptive or similar rights.
Section 242 of DGCL provides that the holders of each class or series of stock will have the right to vote separately as a class on
certain amendments to our restated certificate of incorporation that would affect the class or series of preferred stock, as applicable. This right is in addition to any voting rights that may be provided for in the applicable certificate of
designation.
- 16 -
DESCRIPTION OF WARRANTS
We may issue warrants or other rights. We may issue these securities in such amounts or in as many distinct series as we wish. This section
summarizes the terms of these securities that apply generally. We will describe the financial and other specific terms of any such series of securities in the prospectus supplement accompanying this prospectus. Those terms may vary from the terms
described here.
When we refer to a series of securities in this section, we mean all securities issued as part of the same series under
any applicable indenture, agreement or other instrument. When we refer to the prospectus supplement, we mean the applicable prospectus supplement describing the specific terms of the security you purchase. The terms used in the prospectus supplement
will have the meanings described in this prospectus, unless otherwise specified.
In this section entitled Description of
Warrants, references to Agenus, we, our and us refer only to Agenus Inc. and not to its consolidated subsidiaries. Also, in this section, references to holders mean those who own
warrants or other rights registered in their own names, on the books that we or any applicable trustee or warrant or rights agent maintain for this purpose, and not those who own beneficial interests in warrants registered in street name or in
warrants issued in book-entry form through one or more depositaries. Owners of beneficial interests in warrants should also read the section entitled Legal Ownership and Book-Entry Issuance.
Warrants
The following description of
warrants does not purport to be complete and is qualified in its entirety by reference to the description of a particular series of warrants contained in an applicable prospectus supplement. For information relating to common stock and preferred
stock, see Description of Common Stock and Description of Preferred Stock, respectively.
We may offer by means of
this prospectus warrants for the purchase of our preferred stock or common stock. We may issue warrants separately or together with any other securities offered by means of this prospectus, and the warrants may be attached to or separate from such
securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent specified therein. The warrant agent will act solely as our agent in connection with the warrants of such series
and will not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.
Agreements
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to
this prospectus. Each series of warrants may be evidenced by certificates and may be issued under a separate indenture, agreement or other instrument to be entered into between us and a bank that we select as agent with respect to such series. The
agent, if any, will have its principal office in the U.S. and have a combined capital and surplus of at least $50,000,000. Warrants in book-entry form will be represented by a global security registered in the name of a depositary, which will be the
holder of all the securities represented by the global security. Those who own beneficial interests in a global security will do so through participants in the depositarys system, and the rights of these indirect owners will be governed solely
by the applicable procedures of the depositary and its participants. We describe book-entry securities under Legal Ownership and Book-Entry Issuance.
General Terms of Warrants
The prospectus
supplement relating to a series of warrants will identify the name and address of the warrant agent, if any. The prospectus supplement will describe the following terms, where applicable, of the warrants in respect of which this prospectus is being
delivered:
|
|
|
the title and issuer of the warrants; |
|
|
|
the aggregate number of warrants; |
- 17 -
|
|
|
the price or prices at which the warrants will be issued; |
|
|
|
the currencies in which the price or prices of the warrants may be payable; |
|
|
|
the designation, amount and terms of the securities purchasable upon exercise of the warrants; |
|
|
|
the designation and terms of the other securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of security; |
|
|
|
if applicable, the date on and after which the warrants and any related securities will be separately transferable; |
|
|
|
any securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of such securities may be listed; |
|
|
|
the price or prices at which and currency or currencies in which the securities purchasable upon exercise of the warrants may be purchased; |
|
|
|
the date on which the right to exercise the warrants shall commence and the date on which such right shall expire; |
|
|
|
the minimum or maximum amount of warrants that may be exercised at any one time; |
|
|
|
whether the warrants will be issued in fully registered for or bearer form, in global or non-global form or in any combination of these forms; |
|
|
|
information with respect to book-entry procedures, if any; |
|
|
|
a discussion of certain U.S. federal income tax considerations; and |
|
|
|
any other material terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |
Exercise of Warrants
Unless otherwise
provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to this prospectus. If any warrant is exercisable for other securities or other property, the following provisions will apply.
Each such warrant may be exercised at any time up to any expiration date and time mentioned in the prospectus supplement relating to those warrants. After the close of business on any applicable expiration date, unexercised warrants will become
void.
Warrants may be exercised by delivery of the certificate representing the securities to be exercised, or in the case of global
securities, as described below under Legal Ownership and Book-Entry Issuance, by delivery of an exercise notice for those warrants, together with certain information, and payment to any agent in immediately available funds, as provided
in the prospectus supplement, of the required purchase amount, if any. Upon receipt of payment and the certificate or exercise notice properly executed at the office indicated in the prospectus supplement, we will, in the time period the relevant
agreement provides, issue and deliver the securities or other property purchasable upon such exercise. If fewer than all of the warrants represented by such certificates are exercised, a new certificate will be issued for the remaining amount of
warrants.
If mentioned in the prospectus supplement, securities may be surrendered as all or part of the exercise price for warrants.
Antidilution Provisions
Unless
otherwise provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to this prospectus. In the case of warrants to purchase common stock, the exercise price payable and the number of
shares of common stock purchasable upon warrant exercise may be adjusted in certain events, including:
|
|
|
the issuance of a stock dividend to common shareholders or a combination, subdivision or reclassification of common stock; |
- 18 -
|
|
|
the issuance of rights, warrants or options to all common and preferred shareholders entitling them to purchase common stock for an aggregate consideration per share less than the current market price per share of
common stock; |
|
|
|
any distribution to our common shareholders of evidences of our indebtedness of assets, excluding cash dividends or distributions referred to above; and |
|
|
|
any other events mentioned in the prospectus supplement. |
The prospectus supplement will
describe which, if any, of these provisions shall apply to a particular series of warrants. Unless otherwise specified in the applicable prospectus supplement, no adjustment in the number of shares purchasable upon warrant exercise will be required
until cumulative adjustments require an adjustment of at least 1% of such number and no fractional shares will be issued upon warrant exercise, but we will pay the cash value of any fractional shares otherwise issuable.
Modification
Unless otherwise provided in
the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to this prospectus. We and any agent for any series of warrants may amend any warrant or rights agreement and the terms of the related
warrants by executing a supplemental agreement, without any such warrantholders consent, for the purpose of:
|
|
|
curing any ambiguity, any defective or inconsistent provision contained in the agreement, or making any other corrections to the agreement that are not inconsistent with the provisions of the warrant certificates;
|
|
|
|
evidencing the succession of another corporation to us and its assumption of our covenants contained in the agreement and the securities; |
|
|
|
appointing a successor depository, if the securities are issued in the form of global securities; |
|
|
|
evidencing a successor agents acceptance of appointment with respect to any securities; |
|
|
|
adding to our covenants for the benefit of securityholders or surrendering any right or power we have under the agreement; |
|
|
|
issuing warrants in definitive form, if such securities are initially issued in the form of global securities; or |
|
|
|
amending the agreement and the warrants as we deem necessary or desirable and that will not adversely affect the interests of the applicable warrantholders in any material respect. |
We and any agent for any series of warrants may also amend any agreement and the related warrants by a supplemental agreement with the consent
of the holders of a majority of the warrants of any series affected by such amendment, for the purpose of adding, modifying or eliminating any of the agreements provisions or of modifying the rights of the holders of warrants. However, no such
amendment that:
|
|
|
reduces the number or amount of securities receivable upon any exercise of any such security; |
|
|
|
shortens the time period during which any such security may be exercised; |
|
|
|
otherwise adversely affects the exercise rights of warrantholders in any material respect; or |
|
|
|
reduces the number of securities the consent of holders of which is required for amending the agreement or the related warrants; |
may be made without the consent of each holder affected by that amendment.
- 19 -
Consolidation, Merger and Sale of Assets
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to
this prospectus. Any agreement with respect to warrants will provide that we are generally permitted to merge or consolidate with another corporation or other entity. Any such agreement will also provide that we are permitted to sell our assets
substantially as an entirety to another corporation or other entity or to have another entity sell its assets substantially as an entirety to us. With regard to any series of warrants, however, we may not take any of these actions unless all of the
following conditions are met:
|
|
|
if we are not the successor entity, the person formed by the consolidation or into or with which we merge or the person to which our properties and assets are conveyed, transferred or leased must be an entity organized
and existing under the laws of the United States, any state or the District of Columbia and must expressly assume the performance of our covenants under any relevant indenture, agreement or other instrument; and |
|
|
|
we or that successor corporation must not immediately be in default under that agreement. |
Enforcement by
Holders of Warrants
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any
warrants we issue pursuant to this prospectus. Any agent for any series of warrants will act solely as our agent under the relevant agreement and will not assume any obligation or relationship of agency or trust for any securityholder. A single bank
or trust company may act as agent for more than one issue of securities. Any such agent will have no duty or responsibility in case we default in performing our obligations under the relevant agreement or warrant, including any duty or
responsibility to initiate any legal proceedings or to make any demand upon us. Any securityholder may, without the agents consent or consent of any other securityholder, enforce by appropriate legal action its right to exercise any warrant
exercisable for any property.
Replacement of Certificates
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to
this prospectus. We will replace any destroyed, lost, stolen or mutilated warrant or rights certificate upon delivery to us and any applicable agent of satisfactory evidence of the ownership of that certificate and of its destruction, loss, theft or
mutilation, and (in the case of mutilation) surrender of that certificate to us or any applicable agent, unless we have, or the agent has, received notice that the certificate has been acquired by a bona fide purchaser. That securityholder will also
be required to provide indemnity satisfactory to us and the relevant agent before a replacement certificate will be issued.
Title
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any warrants we issue pursuant to
this prospectus. We, any agents for any series of warrants and any of their agents may treat the registered holder of any certificate as the absolute owner of the securities evidenced by that certificate for any purpose and as the person entitled to
exercise the rights attaching to the warrants so requested, despite any notice to the contrary. See Legal Ownership and Book-Entry Issuance.
- 20 -
DESCRIPTION OF DEBT SECURITIES
We will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be entered into
between Agenus and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture
Act of 1939.
We may offer under this prospectus up to an aggregate principal amount of $150,000,000 in debt securities; or if debt
securities are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold for an initial public offering price of up to $150,000,000. Unless otherwise specified in the applicable
prospectus supplement, the debt securities will represent direct, unsecured obligations of Agenus and will rank equally with all of our other unsecured indebtedness.
The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety to the detailed
provisions of the indenture.
General
We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC.
The prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the
prospectus supplement is delivered:
|
|
|
the title of the series; |
|
|
|
the aggregate principal amount; |
|
|
|
the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities; |
|
|
|
any limit on the aggregate principal amount; |
|
|
|
the date or dates on which principal is payable; |
|
|
|
the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates; |
|
|
|
the date or dates from which interest, if any, will be payable and any regular record date for the interest payable; |
|
|
|
the place or places where principal and, if applicable, premium and interest, is payable; |
|
|
|
the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities; |
|
|
|
the denominations in which such debt securities may be issuable, if other than denominations of $1,000, or any integral multiple of that number; |
|
|
|
whether the debt securities are to be issuable in the form of certificated debt securities (as described below) or global debt securities (as described below); |
|
|
|
the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal amount of the debt securities; |
- 21 -
|
|
|
the currency of denomination; |
|
|
|
the designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest, will be made; |
|
|
|
if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies or currency units other than the currency of denomination, the manner in which the
exchange rate with respect to such payments will be determined; |
|
|
|
if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency or currencies, or by reference to a commodity, commodity index, stock exchange index, or
financial index, then the manner in which such amounts will be determined; |
|
|
|
the provisions, if any, relating to any collateral provided for such debt securities; |
|
|
|
any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture; |
|
|
|
any events of default, if not otherwise described below under Events of Default; |
|
|
|
the terms and conditions, if any, for conversion into or exchange for shares of common stock or preferred stock; |
|
|
|
any depositaries, interest rate calculation agents, exchange rate calculation agents, or other agents; and |
|
|
|
the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to other indebtedness of Agenus. |
We may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon acceleration
of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will
describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement.
We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we
will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement.
Exchange and/or Conversion Rights
We may
issue debt securities which can be exchanged for or converted into shares of common stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities.
Transfer and Exchange
We may issue debt
securities that will be represented by either:
|
|
|
book-entry securities, which means that there will be one or more global securities registered in the name of a depositary or a nominee of a depositary; or |
|
|
|
certificated securities, which means that they will be represented by a certificate issued in definitive registered form. |
We will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry or
certificated securities.
- 22 -
Certificated Debt Securities
Those who hold certificated debt securities may transfer or exchange such debt securities at the trustees office or at the paying
agents office or agency in accordance with the terms of the indenture. There will be no service charge for any transfer or exchange of certificated debt securities but there may be a requirement to pay an amount sufficient to cover any tax or
other governmental charge payable in connection with such transfer or exchange.
Those who hold certificated debt securities may effect
the transfer of certificated debt securities and of the right to receive the principal of, premium, and/or interest, if any, on the certificated debt securities only by surrendering the certificate representing the certificated debt securities and
having us or the trustee issue a new certificate to the new holder.
Global Securities
If we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of
the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities.
The prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued in
global form. None of the Company, the trustee, any payment agent, or the security registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global
debt security or for maintaining, supervising, or reviewing any records relating to these beneficial ownership interests.
No Protection in the Event
of Change of Control
The indenture does not have any covenants or other provisions providing for a put or increased interest or
otherwise that would afford holders of debt securities additional protection in the event of a recapitalization transaction, a change of control of Agenus, or a highly leveraged transaction. If we offer any covenants or provisions of this type with
respect to any debt securities covered by this prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless otherwise indicated in this prospectus or a prospectus supplement, the debt securities will not have the benefit of any covenants that
limit or restrict our business or operations, the pledging of our assets, or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.
Consolidation, Merger, and Sale of Assets
We have agreed in the indenture that we will not consolidate with or merge into any other person, or convey, transfer, sell, or lease our
properties and assets substantially as an entirety to any person, unless:
|
|
|
the person formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred, sold, or leased, is a corporation organized and existing under the
laws of the U.S., any state or the District of Columbia, or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and, if we are not the surviving person, the surviving person has expressly assumed all of our
obligations, including the payment of the principal of, and premium, if any, and interest on the debt securities and the performance of the other covenants under the indenture; and |
- 23 -
|
|
|
immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture.
|
Events of Default
Unless otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture with
respect to debt securities of any series:
|
|
|
we fail to pay any principal or premium, if any, when it becomes due; |
|
|
|
we fail to pay any interest within 30 days after it becomes due; |
|
|
|
we fail to comply with any other covenant in the debt securities or the indenture for 60 days after written notice specifying the failure from the trustee or the holders of not less than 25% in aggregate principal
amount of the outstanding debt securities of that series; and |
|
|
|
certain events involving bankruptcy, insolvency, or reorganization of Agenus or any of our significant subsidiaries. |
The trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal of, or
premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so.
If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency, or reorganization) occurs, and
is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus
the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on
such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if:
|
|
|
all events of default (other than nonpayment of accelerated principal, premium, or interest) have been cured or waived; |
|
|
|
all lawful interest on overdue interest and overdue principal has been paid; and |
|
|
|
the rescission would not conflict with any judgment or decree. |
In addition, if the
acceleration occurs at any time when Agenus has outstanding indebtedness which is senior to the debt securities, the payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any
amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the terms prescribed in the instruments evidencing the senior indebtedness and the indenture.
If an event of default resulting from certain events of bankruptcy, insolvency, or reorganization occurs, the principal, premium, and interest
amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or other act on the part of the trustee or the holders of the debt securities of that series.
The holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing default
or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method, and place of conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the
indenture.
- 24 -
No holder of any debt security of a series will have any right to institute any proceeding with
respect to the indenture or for any remedy under the indenture, unless:
|
|
|
the holder gives to the trustee written notice of a continuing event of default; |
|
|
|
the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written request and offer reasonable indemnity to the trustee to institute a proceeding as
trustee; |
|
|
|
the trustee fails to institute a proceeding within 60 days after such request; and |
|
|
|
the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give the trustee a direction inconsistent with such request during such 60-day period.
|
These limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the
due dates expressed in the debt securities.
Modification and Waiver
From time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture or
the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including:
|
|
|
to provide that the surviving entity following a change of control of Agenus permitted under the indenture will assume all of our obligations under the indenture and debt securities; |
|
|
|
to provide for certificated debt securities in addition to uncertificated debt securities; |
|
|
|
to comply with any requirements of the SEC under the Trust Indenture Act of 1939; |
|
|
|
to cure any ambiguity, defect, or inconsistency, or make any other change that does not materially and adversely affect the rights of any holder; and |
|
|
|
to appoint a successor trustee under the indenture with respect to one or more series. |
From
time to time, we and the trustee may, with the consent of holders of at least a majority in principal amount of the outstanding debt securities, amend or supplement the indenture or the debt securities, or waive compliance in a particular instance
by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder affected by such action, modify or supplement the indenture or the debt securities, or waive compliance with any provision of
the indenture or the debt securities in order to:
|
|
|
reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt security; |
|
|
|
reduce the rate of or change the time for payment of interest; |
|
|
|
reduce the principal of or change the stated maturity of the debt securities; |
|
|
|
make any debt security payable in money other than that stated in the debt security; |
|
|
|
change the amount or time of any payment required, or reduce the premium payable upon any redemption, or change the time before which no such redemption may be made; |
|
|
|
waive a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment; or |
|
|
|
take any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action. |
- 25 -
Defeasance of Debt Securities and Certain Covenants in Certain Circumstances
The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following
certain procedures described in the indenture. These procedures will allow us either:
|
|
|
to defease and be discharged from any and all of our obligations with respect to any debt securities except for the following obligations (which discharge is referred to as legal defeasance):
|
(1) to register the transfer or exchange of such debt securities;
(2) to replace temporary or mutilated, destroyed, lost, or stolen debt securities;
(3) to compensate and indemnify the trustee; or
(4) to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or
|
|
|
to be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as well as any additional covenants which may be contained in the applicable supplemental
indenture (which release is referred to as covenant defeasance). |
In order to exercise either defeasance option,
we must deposit with the trustee or other qualifying trustee, in trust for that purpose:
|
|
|
U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) which through the scheduled payment of principal and interest in accordance with their terms will provide money; or
|
|
|
|
a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion of a nationally-recognized firm of independent accountants to provide money;
|
which in each case specified above, provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on the
debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture.
In addition, defeasance may be effected only if, among other things:
|
|
|
in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture, stating that as a result of the defeasance neither the trust nor the trustee will be
required to register as an investment company under the Investment Company Act of 1940; |
|
|
|
in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there has been published by, the Internal Revenue Service a ruling to the effect that, or there has
been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities will not recognize income, gain, or loss for U.S. federal income tax purposes solely as a
result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and at the same times as would have been the case if legal defeasance had not occurred;
|
|
|
|
in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding debt securities will not recognize income, gain, or loss for U.S. federal income tax
purposes as a result of covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, and at the same times as would have been the case if covenant defeasance had not occurred; and |
|
|
|
certain other conditions described in the indenture are satisfied. |
- 26 -
If we fail to comply with our remaining obligations under the indenture and applicable
supplemental indenture after a covenant defeasance of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of any undefeased event of default, the amount of money and/or
U.S. Government Obligations and/or Foreign Government Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration. We will, however, remain liable in
respect of these payments.
The term U.S. Government Obligations as used in the above discussion means securities which are
direct obligations of or non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged.
The term Foreign Government Obligations as used in the above discussion means, with respect to debt securities of any series that
are denominated in a currency other than U.S. dollars (1) direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged or (2) obligations of
a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which in either case under clauses
(1) or (2), are not callable or redeemable at the option of the issuer.
Regarding the Trustee
We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable debt
securities. You should note that if the trustee becomes a creditor of Agenus, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received
in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any
conflicting interest within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign.
The
holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method, and place of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and
is continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise
any of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee reasonable indemnity or security.
- 27 -
DESCRIPTION OF UNITS
This section outlines some of the provisions of the units and the unit agreements that we may enter into. This information may not be complete
in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The specific terms of any series of units will be described in the applicable prospectus supplement. If so described in
a particular supplement, the specific terms of any series of units may differ from the general description of terms presented below.
In
this section entitled Description of Units, references to Agenus, we, our and us refer only to Agenus Inc. and not to its consolidated subsidiaries. Also, in this section, references to
holders mean those who own units registered in their own names, on the books that we or our agent maintain for this purpose, and not those who own beneficial interests in units registered in street name or in units issued in book-entry
form through one or more depositaries. Owners of beneficial interests in the units should read the section below entitled Legal Ownership and Book-Entry Issuance.
We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock, and warrants in any
combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement
under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.
The applicable prospectus supplement may describe:
|
|
|
the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |
|
|
|
any provisions of the governing unit agreement that differ from those described below; and |
|
|
|
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units. |
The provisions described in this section, as well as those described under Description of Common Stock, Description of
Preferred Stock, Description of Warrants and Description of Debt Securities will apply to the securities included in each unit, to the extent relevant.
Issuance in Series
We may issue units in
such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus
supplement.
Unit Agreements
Unless
otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this prospectus. We will issue the units under one or more unit agreements to be entered into between us and a bank or
other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of units will be issued and the unit agent under that agreement in the applicable
prospectus supplement.
The following provisions will generally apply to all unit agreements unless otherwise stated in the applicable
prospectus supplement.
- 28 -
Enforcement of Rights
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this
prospectus. The unit agent under a unit agreement will act solely as our agent in connection with the units issued under that agreement. The unit agent will not assume any obligation or relationship of agency or trust for or with any holders of
those units or of the securities comprising those units. The unit agent will not be obligated to take any action on behalf of those holders to enforce or protect their rights under the units or the included securities.
Except as indicated in the next paragraph, a holder of a unit may, without the consent of the unit agent or any other holder, enforce its
rights as holder under any security included in the unit, in accordance with the terms of that security and the indenture, warrant agreement, rights agreement or other instrument under which that security is issued. Those terms are described
elsewhere in this prospectus under the sections relating to debt securities, preferred stock, common stock or warrants, as relevant.
Notwithstanding the foregoing, a unit agreement may limit or otherwise affect the ability of a holder of units issued under that agreement to
enforce its rights, including any right to bring a legal action, with respect to those units or any securities, other than debt securities, that are included in those units. Limitations of this kind will be described in the applicable prospectus
supplement.
Modification without Consent of Holders
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this
prospectus. We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder:
|
|
|
to correct or supplement any defective or inconsistent provision; or |
|
|
|
to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. |
We do not need any approval to make changes that affect only units to be issued after the changes take effect. We may also make changes that
do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any
required approvals from the holders of the affected units.
Modification with Consent of Holders
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this
prospectus. We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that unit, if the amendment would:
|
|
|
impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or
enforcement of that right; or |
|
|
|
reduce the percentage of outstanding units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as
described below. |
- 29 -
Any other change to a particular unit agreement and the units issued under that agreement would
require the following approval:
|
|
|
if the change affects only the units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding units of that series; or |
|
|
|
if the change affects the units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding units of all series affected by the change, with the units of all
the affected series voting together as one class for this purpose. |
These provisions regarding changes with majority
approval also apply to changes affecting any securities issued under a unit agreement, as the governing document.
In each case, the
required approval must be given by written consent.
Unit Agreements Will Not Be Qualified Under Trust Indenture Act
No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act.
Therefore, holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units.
Mergers
and Similar Transactions Permitted; No Restrictive Covenants or Events of Default
Unless otherwise provided in the applicable
prospectus supplement, the following provisions will apply to any units we issue pursuant to this prospectus. The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity
or to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the
unit agreements. We will then be relieved of any further obligation under these agreements.
The unit agreements will not include any
restrictions on our ability to put liens on our assets, including our interests in our subsidiaries, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the
occurrence of any events of default.
Governing Law
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this
prospectus. The unit agreements and the units will be governed by New York law.
Form, Exchange and Transfer
Unless otherwise provided in the applicable prospectus supplement, the following provisions will apply to any units we issue pursuant to this
prospectus. We will issue each unit in globalthat is, book-entryform only. Units in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the units represented by
the global security. Those who own beneficial interests in a unit will do so through participants in the depositarys system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its
participants. We describe book-entry securities below under Legal Ownership and Book-Entry Issuance.
In addition, we will
issue each unit in registered form, unless we say otherwise in the applicable prospectus supplement. Bearer securities would be subject to special provisions, as we describe below under Securities Issued in Bearer Form.
- 30 -
Each unit and all securities comprising the unit will be issued in the same form.
If we issue any units in registered, non-global form, the following will apply to them.
The units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their units for units of
smaller denominations or combined into fewer units of larger denominations, as long as the total amount is not changed.
|
|
|
Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions
or perform them ourselves. |
|
|
|
Holders will not be required to pay a service charge to transfer or exchange their units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer
or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holders proof of legal ownership. The transfer agent may also require an indemnity before replacing any units. |
|
|
|
If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right as to less than all those units or other securities, we may block the exchange or transfer of those units
during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit
selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes
securities that are or may be selected for early settlement. |
Only the depositary will be entitled to transfer or exchange a
unit in global form, since it will be the sole holder of the unit.
Payments and Notices
In making payments and giving notices with respect to our units, we will follow the procedures we plan to use with respect to our debt
securities, where applicable.
- 31 -
LEGAL OWNERSHIP AND BOOK-ENTRY ISSUANCE
We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable depositary or warrant agent maintain for this purpose as the holders of those securities. These persons are the
legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as indirect holders of those securities. As we discuss below,
indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.
Book-Entry
Holders
Except as described below, we will issue securities in book-entry form only, as we will specify in the applicable prospectus
supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositarys
book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.
Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in
the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes
along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their
customers; they are not obligated to do so under the terms of the securities.
As a result, investors in a book-entry security will not
own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositarys book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.
Street Name Holders
We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to
hold their securities in their own names or in street name. Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would
hold only a beneficial interest in those securities through an account he or she maintains at that institution.
For securities held in
street name, we or any applicable depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such depositary will
make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally
required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.
Legal Holders
Our obligations, as well as the obligations of any applicable depositary or warrant agent or other third party employed by us or any
of the foregoing, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor
chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.
- 32 -
For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the
approval of the holders to amend an instrument defining the rights of security holders, to relieve us of the consequences of a breach or of our or its obligation to comply with a particular provision of such an instrument or for other purposes. In
such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the legal holders.
Special Considerations for Indirect Holders
If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check
with your own institution to find out:
|
|
|
how it handles securities payments and notices; |
|
|
|
whether it imposes fees or charges; |
|
|
|
how it would handle a request for the holders consent, if ever required; |
|
|
|
whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; |
|
|
|
how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and |
|
|
|
if the securities are in book-entry form, how the depositarys rules and procedures will affect these matters. |
Global Securities
A global security is a
security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.
Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless specified otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York
(DTC), will be the depositary for all securities issued in book-entry form.
A global security may not be transferred to or
registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under Special Situations When a Global Security Will Be
Terminated. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial
interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor
whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.
If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system.
- 33 -
Special Considerations for Global Securities
As an indirect holder, an investors rights relating to a global security will be governed by the account rules of the investors
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a legal holder of securities and instead deal only with the depositary that holds the global security.
If securities are issued only in the form of a global security, an investor should be aware of the following:
|
|
|
An investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below.
|
|
|
|
An investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above.
|
|
|
|
An investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form. |
|
|
|
An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order
for the pledge to be effective. |
|
|
|
The depositarys policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investors interest in a global security. We and any applicable agent
have no responsibility for any aspect of the depositarys actions or for its records of ownership interests in a global security. We and any applicable agent also will not supervise the depositary in any way. |
|
|
|
The depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well. |
|
|
|
Financial institutions that participate in the depositarys book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices
and other matters relating to the securities. |
|
|
|
There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. |
Special Situations When A Global Security Will Be Terminated
In a few special situations described below, the global security will terminate, and interests in it will be exchanged for physical
certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests
in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above.
The global security will terminate when the following special situations occur:
|
|
|
if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
|
|
|
|
if we notify any applicable depositary or warrant agent that we wish to terminate that global security; or |
|
|
|
if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. |
- 34 -
The applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and not us or any applicable agent, is responsible for deciding the names of the
institutions that will be the initial direct holders.
- 35 -
PLAN OF DISTRIBUTION
We may sell the securities covered by this prospectus directly to purchasers or through underwriters, broker-dealers or agents, who may
receive compensation in the form of discounts, concessions or commissions from us. These discounts, concessions or commissions as to any particular underwriter, broker-dealer or agent may be in excess of those customary in the types of transactions
involved. In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders.
The securities may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices
determined at the time of sale or at negotiated prices. These sales may be effected in transactions which may involve crosses or block transactions.
If underwriters are used in an offering of securities, such offered securities may be resold in one or more transactions:
|
|
|
on any national securities exchange or quotation service on which the preferred stock or the common stock may be listed or quoted at the time of sale, including, as of the date of this prospectus, the NASDAQ Capital
Market in the case of the common stock; |
|
|
|
in the over-the-counter market; |
|
|
|
in transactions otherwise than on these exchanges or services or in the over-the-counter market; or |
|
|
|
through the writing of options, whether the options are listed on an options exchange or otherwise. |
Each prospectus supplement will state the terms of the offering, including, but not limited to:
|
|
|
the names of any underwriters, dealers, or agents; |
|
|
|
the public offering or purchase price of the securities and the net proceeds that we will receive from the sale; |
|
|
|
any underwriting discounts and commissions or other items constituting underwriters compensation; |
|
|
|
any discounts, commissions, or fees allowed or paid to dealers or agents; and |
|
|
|
any securities exchange on which the offered securities may be listed. |
If we sell securities
to underwriters, we will execute an underwriting agreement with them at the time of the sale and will name them in the applicable prospectus supplement. In connection with these sales, the underwriters may be deemed to have received compensation in
the form of underwriting discounts and commissions. The underwriters also may receive commissions from purchasers of securities for whom they may act as agent. Unless we specify otherwise in the applicable prospectus supplement, the underwriters
will not be obligated to purchase the securities unless the conditions set forth in the underwriting agreement are satisfied, and if the underwriters purchase any of the securities offered by such prospectus supplement, they will be required to
purchase all of such offered securities. The underwriters may acquire the securities for their own account and may resell the securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering
price or varying prices determined at the time of sale. The underwriters may sell the securities to or through dealers, and those dealers may receive discounts, concessions, or commissions from the underwriters as well as from the purchasers for
whom they may act as agent.
We may designate agents who agree to use their reasonable efforts to solicit purchasers for the period of
their appointment or to sell securities on a continuing basis. We may also sell securities directly to one or more purchasers without using underwriters or agents.
- 36 -
Under agreements entered into with us, underwriters and agents may be entitled to indemnification
by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution for payments the underwriters or agents may be required to make. The underwriters, agents, and their affiliates may engage in financial or
other business transactions with us and our subsidiaries in the ordinary course of business.
The aggregate proceeds to us from the sale
of the securities will be the purchase price of the securities less discounts and commissions, if any.
In order to comply with the
securities laws of certain states, if applicable, any securities covered by this prospectus must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states securities may not be sold unless
they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in
any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases
previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels.
Any such underwriters are not required to engage in these activities and may end any of these activities at any time.
The applicable
prospectus supplement may provide that the original issue date for your securities may be more than three scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date
prior to the third business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for
your securities, to make alternative settlement arrangements to prevent a failed settlement.
The securities may be new issues of
securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities.
In order to comply with the securities laws of some states, if applicable, the shares of common stock offered by this prospectus must be sold
in such jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from
the registration or qualification requirement is available and is complied with.
To the extent required, this prospectus may be amended
or supplemented from time to time to describe a specific plan of distribution.
Transfer Agent
The transfer agent and registrar for Agenus common stock is American Stock Transfer & Trust Company. Its telephone number is
(800) 937-5449.
- 37 -
LEGAL MATTERS
The validity of the securities that may be offered hereby will be passed upon for us by Choate, Hall & Stewart LLP.
- 38 -
EXPERTS
The consolidated financial statements of Agenus Inc., as of December 31, 2013 and 2012, and for each of the years in the three-year
period ended December 31, 2013, and managements assessment of the effectiveness of internal control over financial reporting as of December 31, 2013 have been incorporated by reference herein and in the registration statement in
reliance upon the reports of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
The audited historical financial statements of 4-Antibody AG, incorporated by reference into our Current Report on Form 8-K filed
February 13, 2014 (as amended by our Current Report on Form 8-K/A filed April 29, 2014), have been incorporated by reference herein in reliance on the report of Ernst & Young Ltd, independent auditors to 4-Antibody AG, given on
the authority of such firm as experts in accounting and auditing.
- 39 -
WHERE YOU CAN FIND MORE INFORMATION
Agenus Inc. is subject to the information requirements of the Securities Exchange Act of 1934, as amended, and files annual, quarterly and
special reports, proxy statements and other information with the SEC. You may read and copy any materials we file with the SEC at the Public Reference Room of the SEC at Room 1580, 100 F Street, N.E., Washington, D.C. 20549. You may obtain
information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, we file many of our documents electronically with the SEC, and you may access those documents over the Internet. The SEC maintains a web
site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of the SECs website is http://www.sec.gov. Documents we have filed with the SEC are also
available on our website through the investor link at www.agenusbio.com. Information contained on our web site does not constitute a part of this prospectus and is not incorporated by reference herein.
- 40 -
$150,000,000
of
Common Stock
Preferred Stock
Warrants
Debt Securities
Units
PROSPECTUS
, 2014
The information contained in this prospectus is not complete and may be changed. A
registration statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This
prospectus is not an offer to sell these securities, and is not soliciting an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction where such offer, solicitation or sale is not permitted or would be
unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Subject To Completion, Dated October 10, 2014
PROSPECTUS
Agenus Inc.
10,000,000 Shares of Common Stock
This prospectus
relates to the issuance and sale of up to 10,000,000 shares of our common stock from time to time through our sales agent, MLV & Co. LLC. These sales, if any, will be made pursuant to the terms of a sales agreement between us and the sales
agent, which is filed with the Securities and Exchange Commission (SEC) as an exhibit to the registration statement of which this prospectus is a part.
Our common stock trades on the NASDAQ Capital Market (NASDAQ) under the symbol AGEN. Sales of shares of our common stock under
this prospectus, if any, may be made by any method deemed to be an at the market offering as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the NASDAQ, the existing trading market
for our common stock. The sales agent is not required to sell any specific number of shares of our common stock. The sales agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the
shares, on mutually agreed terms between the sales agent and us. On October 8, 2014, the last reported sales price of our common stock on the NASDAQ was $2.81 per share. There is no arrangement for funds to be received in any escrow, trust or
similar arrangement.
The compensation payable to the sales agent for sales of common stock sold pursuant to the sales agreement will be
an aggregate of 3% of the gross proceeds of the sales price of common stock sold. The net proceeds from any sales under this prospectus will be used as described under Use of Proceeds. The proceeds that we receive from sales of our
common stock will depend on the number of shares actually sold and the offering price of such shares.
In connection with the sale of
common stock on our behalf, MLV may, and will with respect to sales effected in an at the market offering, be deemed to be an underwriter within the meaning of the Securities Act, and the compensation of MLV may be deemed to be
underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the sales agent against certain liabilities, including liabilities under the Securities Act.
You should read carefully and consider the Risk Factors referenced on page 6 of this prospectus and
the risk factors described in other documents incorporated by reference herein.
Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is
, 2014.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus and the documents incorporated into each by reference include important information about us, the shares being offered and
other information you should know before investing in our common stock.
You should rely on this prospectus and the information
incorporated or deemed to be incorporated by reference in this prospectus. We have not, and the sales agent has not, authorized anyone to provide you with information that is in addition to or different from that contained or incorporated by
reference in this prospectus. We are not, and the sales agent is not, offering to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference
in this prospectus is accurate as of any date other than as of the date of this prospectus or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus or any sale of our
common stock. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates.
All
references in this prospectus to Agenus, the Company, we, us or our mean Agenus Inc. and its subsidiaries, unless we state otherwise or the context otherwise requires.
- 1 -
CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS
This prospectus, the documents incorporated by reference herein and therein and other written and oral statements we make from time to time
contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the fact
they use words such as could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe,
will, potential, opportunity, future and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify
forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could
delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements are likely to relate to, among other things, our business strategy, our research and development, our product
development efforts, our ability to commercialize our product candidates, the activities of our licensees, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting
pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations and intentions.
Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in
forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. We undertake no obligation to release publicly any revisions to forward-looking statements as
a result of new information, future events or otherwise.
We have included more detailed descriptions of these risks and uncertainties and
other risks and uncertainties applicable to our business that we believe could cause actual results to differ materially from any forward-looking statement in the Risk Factors sections of this prospectus and the documents incorporated by
reference herein including, but not limited to, the risk factors incorporated by reference from our filings with the SEC. We encourage you to read those descriptions carefully. We caution investors not to place significant reliance on
forward-looking statements; such statements need to be evaluated in light of all the information contained and incorporated by reference in this prospectus. Furthermore, the statements speak only as of the date of each document, and we undertake no
obligation to update or revise these statements.
Retrocyte Display® and Stimulon® are registered trademarks of Agenus Inc. and its subsidiaries. All rights reserved.
- 2 -
PROSPECTUS SUMMARY
The following is a summary of selected information contained elsewhere or incorporated by reference. It does not contain all of the
information that you should consider before buying our securities. You should read this prospectus in its entirety, including the information incorporated by reference herein and therein.
The Company
Our Business
Agenus Inc. (including its subsidiaries, also referred to as Agenus, the Company, we, us, and
our) is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein (HSP)-based vaccines and adjuvants. We are focused on immunotherapeutic products based on our core
platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. We assess the development, commercialization
and/or partnering strategies with respect to each of our internal product candidates periodically based on several factors, including clinical trial results, competitive positioning, and funding requirements and resources.
Our Retrocyte Display® technology platform and CPM antibody programs became part of
our portfolio with the acquisition of 4-Antibody AG (4-AB), a European-based biopharmaceutical company, in February 2014. The Retrocyte Display® technology platform is intended to
enable, among other things, the rapid generation and optimization of fully-human and humanized monoclonal antibodies against a broad range of target antigens of interest. We currently have six pre-clinical CPM antibody programs, which target GITR,
OX40, CTLA-4, PD-1, TIM-3 and LAG-3. Although we envision using Retrocyte Display® to drive the discovery of future CPM antibody candidates, not all candidates will necessarily be derived from
the use of this technology. For example, our current antibody candidates targeting GITR were derived independently of Retrocyte Display®. We have selected product candidates targeting GITR
(agonists) and CTLA-4 (antagonists) to advance into investigational new drug applications (INDs) enabling development. In addition, we plan to identify development candidates for the other four CPM antibody programs within the next six
months, in order to be in a position to file INDs on at least four candidates within the next two years. During the quarter ended June 30, 2014, we entered into a collaboration and license agreement with Merck to discover and optimize
fully-human antibodies against two undisclosed cancer targets using the Retrocyte Display®. Under this agreement, Merck will be responsible for the clinical development and commercialization
of antibodies generated under the collaboration, and we are eligible to receive approximately $100 million in potential payments associated with the completion of certain clinical, regulatory and commercial milestones, as well as royalty payments on
worldwide product sales. We are exploring other potential partnering opportunities for our Retrocyte Display® technology platform and CPM antibody programs.
Our Prophage Series cancer vaccines are based on our HSP technology platform. Our Prophage Series vaccines are autologous therapies derived
from cells extracted from the patients tumor. As a result, Prophage Series vaccines contain a precise antigenic fingerprint of a patients particular cancer and are designed to reprogram the bodys immune system to target
only cells bearing this fingerprint, reducing the risk that powerful anti-cancer agents will target healthy tissue and cause debilitating side effects often associated with chemotherapy and radiation therapy. We believe that in contrast to many
other autologous vaccines that are based on cellular preparations, the Prophage Series vaccines are based on a stable protein preparation produced by a less complex manufacturing process. Our Prophage Series vaccines are currently being studied in
two different settings of glioblastoma multiforme, or GBM: newly diagnosed and recurrent disease. In July 2014, we announced final results from a single-arm, open-label Phase 2 trial showing that patients with newly-diagnosed glioblastoma who
received the Prophage vaccine in addition to the standard of care had a survival benefit over patients who received standard of care alone.
- 3 -
Also within our HSP technology platform is HerpV, a recombinant, synthetic vaccine
containing multiple antigens derived from the herpes simplex 2 virus. Combining our HSP technology and our QS-21 Stimulon® adjuvant, HerpV represents a potential new approach to the treatment
of genital herpes. In November 2013, we released top line results from a Phase 2, randomized, double blind, multicenter clinical trial of HerpV in HSV-2 positive genital herpes patients, which showed that the trial met its primary endpoint. In June
2014, we announced that the majority of patients showed an immune response to the HSV antigens after a series of vaccinations and a booster dose at six months. More than half of those vaccinated developed a robust anti-HSV cytotoxic T-cell immune
response, and in those patients there was a statistically significant reduction in viral load, which is believed to be relevant in the reduction of transmission and symptoms. After the booster shot, HerpV demonstrated a durable reduction in viral
shedding approximating 14%, and remains consistent with the reduction in viral shedding observed during the initial treatment period. HerpV evokes immune responses to the mix of HSV2 peptides contained in the vaccine in a substantial majority of
patients. We believe that this is the first demonstration of a correlation between immune response and a statistically significant reduction in viral load. We are currently seeking a partner for the further development of our HerpV program.
Notwithstanding these data, it is uncertain whether the degree of benefit conferred by HerpV will be sufficient to (i) warrant additional clinical trials funded by us or (ii) attract a development partner.
Our QS-21 Stimulon® vaccine adjuvant is a saponin extracted from the bark of the
Quillaja saponaria tree, an evergreen tree native to warm temperate central Chile. QS-21 Stimulon has become a key component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases and,
investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been studied in approximately 50,000 patients. Our QS-21 Stimulon is extensively partnered with GlaxoSmithKline (GSK) and
JANSSEN Alzheimer Immunotherapy (JANSSEN AI) and includes several vaccine candidates in Phase 2 and Phase 3 clinical trials. In July 2014, GSK submitted to the European Medicines Agency an application for marketing approval of its
malaria vaccine candidate incorporating QS-21 Stimulon. If any of our partners products containing QS-21 Stimulon successfully complete clinical development and receive approval for commercial sale, we are generally entitled to receive
milestone payments as well as royalties for 10 years after commercial launch, with some exceptions.
In addition to our internal
development efforts, we continue to pursue collaborative, out-licensing and/or partnering opportunities for our portfolio programs and product candidates, as well as explore in-licensing, acquisitions and collaborative arrangements in areas of
synergy with our existing programs. Our business activities have included product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development, business development,
and support of our collaborations.
We have financed our operations primarily through the sale of equity and debt securities. We believe
that, based on our current plans and activities, our working capital resources at June 30, 2014, plus potential proceeds from our existing license, supply, and collaborative agreements, will be sufficient to satisfy our liquidity requirements
through the first half of 2015. We expect to attempt to raise additional funds in advance of depleting our current funds. We may attempt to raise funds by: (1) pursuing collaborative, out-licensing and/or partnering opportunities for our
portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing and/or (5) selling equity securities. Satisfying
long-term liquidity needs may require the successful commercialization and/or substantial out-licensing or partnering arrangements for our Retrocyte Display® technology platform, CPM antibody
programs, HerpV and the Prophage Series vaccines, and vaccines containing QS-21 Stimulon under development by our licensees. Our long term success will also be dependent on the successful identification, development and commercialization of
potential other product candidates, each of which will require additional capital with no certainty of timing or probability of success. If we incur operating losses for longer than we expect and/or we are unable to raise additional capital, we may
become insolvent and be unable to continue our operations.
- 4 -
You can find more information about us in our filings with the Securities and Exchange
Commission referenced in the sections in this document titled Where You Can Find More Information and Incorporation of Certain Documents by Reference beginning on page 15.
Risk Factors
Before purchasing any of
the securities you should carefully consider the risk factors relating to Agenus incorporated by reference in this prospectus from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, as well as the risks, uncertainties and
additional information set forth in our SEC reports on Forms 10-K, 10-Q and 8-K and in the other documents incorporated by reference in this prospectus. For a description of these reports and documents, and information about where you can find them,
see Where You Can Find More Information and Incorporation of Certain Documents By Reference. Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely
affect our financial condition, results of operations, business and prospects.
Corporate Information
Our principal executive office is located at 3 Forbes Road, Lexington, MA, 02421, and our telephone number is (781) 674-4400. Our website
address is www.agenusbio.com. Information contained on our website is not a part of this prospectus.
The Offering
The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not
contain all the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled Description of Common Stock.
Common stock offered |
Up to 10,000,000 shares |
Sales Agent |
MLV & Co. LLC |
Risk factors |
Your investment in our common shares involves substantial risks. You should consider the Risk Factors included and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our filings
with the SEC. |
Use of Proceeds |
We intend to use the net proceeds from this offering for general corporate purposes which may include working capital, capital expenditures, repayment and refinancing of debt, research and development expenditures, clinical trial expenditures,
acquisitions of additional companies or technologies and investments. We may temporarily invest the net proceeds in investment-grade, interest-bearing securities until they are used for their stated purpose. We have not determined the amount of net
proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. |
- 5 -
RISK FACTORS
Before purchasing any of the securities you should carefully consider the risk factors relating to Agenus incorporated by reference in this
prospectus from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms 10-K, 10-Q and 8-K and in the other documents
incorporated by reference in this prospectus. For a description of these reports and documents, and information about where you can find them, see Where You Can Find More Information and Incorporation of Certain Documents By
Reference. Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects.
- 6 -
USE OF PROCEEDS
We intend to use the net proceeds from this offering for general corporate purposes which may include working capital, capital expenditures,
repayment and refinancing of debt, research and development expenditures, clinical trial expenditures, acquisitions of additional companies or technologies and investments. We may temporarily invest the net proceeds in investment-grade,
interest-bearing securities until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net
proceeds.
- 7 -
DILUTION
If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the public offering price
per share and the as-adjusted net tangible book value per share after this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of
outstanding shares of our common stock.
Our net tangible book value as of June 30, 2014 was $38,081,869, or $0.61 per share of
common stock. After giving effect to the sale of our common stock in the aggregate amount of $31,100,000 at an assumed offering price of $3.11 per share, the last reported sale price of our common stock on NASDAQ as of September 30, 2014, and
after deducting estimated offering commissions and expenses payable by us, our net tangible book value as of June 30, 2014 would have been $72,652,214, or $0.94 per share of common stock. This represents an immediate increase in the net
tangible book value of $0.33 per share to our existing stockholders and an immediate and substantial dilution in net tangible book value of $2.17 per share to new investors. The following table illustrates this per share dilution:
|
|
|
|
|
Assumed offering price per share |
|
$ |
3.11 |
|
Net tangible book value per share as of June 30, 2014 |
|
$ |
0.61 |
|
Increase in net tangible book value per share after this offering |
|
$ |
0.33 |
|
As-Adjusted net tangible book value per share as of June 30, 2014, after giving effect to this offering |
|
$ |
0.94 |
|
Dilution per share to new investors in this offering |
|
$ |
2.17 |
|
The above discussion and table are based on approximately 62,652,000 shares of our common stock
outstanding as of June 30, 2014 and does not include:
|
|
|
2,951,450 shares issuable upon the exercise of outstanding or issuable warrants with a weighted-average exercise price of $10.87 per share; |
|
|
|
6,995,648 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $4.52 per share; |
|
|
|
87,202 nonvested shares; |
|
|
|
333,333 shares issuable upon the conversion of our outstanding shares of series A-1 convertible preferred stock |
|
|
|
166,666 shares issuable under our Employee Stock Purchase Plan; and |
|
|
|
176,029 shares issuable under our Directors Deferred Compensation Plan. |
- 8 -
DESCRIPTION OF COMMON STOCK
General
Each share of Agenus
common stock has the same relative rights and is identical in all respects with each other share of common stock.
Voting Rights
Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of common stock
are entitled to receive dividends out of assets legally available for payment of dividends, as the board may from time to time determine. Each stockholder is entitled to one vote for each share of common stock held on all matters submitted to a vote
of stockholders. Our certificate of incorporation does not provide for cumulative voting for the election of directors, which means that the holders of a majority of the shares voted can elect all of the directors then standing for election. The
common stock is not entitled to preemptive rights and is not subject to conversion or redemption. Each outstanding share of common stock offered by this prospectus will, when issued, be fully paid and nonassessable.
Dividends
Holders of common stock are
entitled to share ratably in any dividends declared by our board of directors, subject to any preferential dividend rights of any outstanding preferred stock. Dividends consisting of shares of common stock may be paid to holders of shares of common
stock. We have never declared or paid cash dividends on our common stock. We do not intend to pay cash dividends in the foreseeable future.
Preemptive
Rights
Holders of common stock do not have any preemptive rights with respect to any shares that may be issued by Agenus in the
future. Thus, Agenus may sell shares of its common stock without first offering them to the then holders of common stock.
Liquidation
In the event of any liquidation or dissolution of Agenus, whether voluntary or involuntary, the holders of Agenus common stock would be
entitled to receive pro rata, after payment of all debts and liabilities of Agenus, all assets of Agenus available for distribution, subject to the rights of the holders of any preferred stock which may be issued with a priority in liquidation or
dissolution over the holders of common stock.
Listing
Our common stock is listed on The NASDAQ Capital Market under the symbol AGEN. On October 8, 2014, the last reported sale
price for our common stock on The NASDAQ Capital Market was $2.81 per share. As of October 6, 2014, we had approximately 1,382 stockholders of record.
Anti-Takeover Provisions
Statutory Business
Combination Provision
Delaware has adopted a business combination statute (Section 203 of the DGCL) that may also have
additional anti-takeover effects to provisions in Agenus restated certificate of incorporation and bylaws. Section 203 of the DGCL, which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any business
combination with an interested stockholder for a period of three years following the time that such stockholder became an interested stockholder, unless:
|
|
|
the board of directors of the corporation approves either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder, prior to the time the interested stockholder
attained that status; |
- 9 -
|
|
|
upon the closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding, for purposes of determining the number of shares outstanding, those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
|
|
|
at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at
least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
With certain exceptions, an
interested stockholder is a person or group who or which owns 15% or more of the corporations outstanding voting stock (including any rights to acquire stock pursuant to an option, warrant, agreement, arrangement or understanding,
or upon the exercise of conversion or exchange rights, and stock with respect to which the person has voting rights only), or is an affiliate or associate of the corporation and was the owner of 15% or more of such voting stock at any time within
the previous three years.
In general, Section 203 defines a business combination to include:
|
|
|
any merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
|
|
|
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; |
|
|
|
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
|
|
|
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. |
A Delaware corporation may opt out of this provision with an express provision in its original certificate of incorporation or an
express provision in its amended and restated certificate of incorporation or bylaws resulting from a stockholders amendment approved by at least a majority of the outstanding voting shares. However, Agenus has not opted out of
this provision. Section 203 could prohibit or delay mergers or other takeover or change-in-control attempts and, accordingly, may discourage attempts to acquire Agenus.
Size of the Board and Vacancies
Our
bylaws provide that the exact number of directors is determined by resolution of the board of directors or by the stockholders at the annual meeting. Our board of directors has the right to fill any vacancies resulting from death, resignation,
disqualification or removal, as well as any newly created directorships arising from an increase in the size of the board.
Amendment of Charter
Provisions
The affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our voting
stock, voting together as a single class, is required to, among other things, amend, alter, change or repeal certain provisions of our restated certificate of incorporation. Our bylaws may only be amended (or new bylaws adopted) by the board of
directors or the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our voting stock represented in person or by proxy at the meeting at which the amendment is voted on.
- 10 -
Undesignated Preferred Stock
We could issue preferred stock that could have other rights, including economic rights senior to our common stock, so that the issuance of the
preferred stock could adversely affect the market value of our common stock. The issuance of the preferred stock may also have the effect of delaying, deferring or preventing a change in control of Agenus without any action by the stockholders. The
effects of issuing preferred stock could include one or more of the following:
|
|
|
restricting dividends on the common stock; |
|
|
|
diluting the voting power of the common stock; |
|
|
|
impairing the liquidation rights of the common stock; or |
|
|
|
discouraging, delaying or preventing changes in control or management of Agenus. |
Transfer Agent
The transfer agent and registrar for Agenus common stock is American Stock Transfer & Trust Company. Its telephone number is
(800) 937-5449.
- 11 -
PLAN OF DISTRIBUTION
We have entered into a sales agreement, dated as of October 10, 2014, with MLV & Co. LLC. the sales agent, under which we may
sell an aggregate of 10,000,000 shares of our common stock from time to time through the sales agent. The sales agent may sell the common stock by any method that is deemed to be an at the market offering as defined in Rule 415 of the
Securities Act, including sales made directly on the NASDAQ Capital Market or on any other existing trading market for the common stock. The sales agent may also sell the common stock in negotiated transactions, subject to our prior approval.
Each time that we wish to issue and sell common stock under the sales agreement, we will agree with the sales agent on the number of shares to
be issued, the dates on which such sales are anticipated to be made and any minimum price below which sales may not be made. Once we have so instructed the sales agent, the sales agent has agreed to use its commercially reasonable efforts consistent
with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The settlement between us and the sales agent of our common stock is generally anticipated to occur on the third trading day following the date
on which the sale was made. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. The obligation of the sales agent under the sales agreement to sell our common stock is subject to a number of conditions that
we must meet.
We will pay the sales agent a total commission equal to an aggregate of 3% of the gross proceeds we receive from the sales
of our common stock. Because there is no minimum offering amount required as a condition to closing this offering, the actual total public offering amount, commissions and proceeds to us, if any, is not determinable at this time.
In connection with the sale of common stock on our behalf, MLV may, and will with respect to sales effected in an at the market
offering, be deemed to be an underwriter within the meaning of the Securities Act, and the compensation of MLV may be deemed to be underwriting commissions or discounts. We have agreed to indemnify the sales agent against certain civil
liabilities, including liabilities under the Securities Act.
Sales of our common stock as contemplated in this prospectus will be settled
through the facilities of The Depository Trust Company or by such other means as we and the sales agent may agree upon.
The offering of
our common stock pursuant to the sales agreement will terminate on the earliest of (1) the sale of all of our common stock subject to the sales agreement, or (2) termination of the sales agreement by us or the sales agent. The sales agent
may terminate the sales agreement at any time in certain circumstances, including the occurrence of a material adverse change that, in the sales agents reasonable judgment, may impair its ability to sell the common stock, our failure to
satisfy any condition under the sales agreement or a suspension or limitation of trading of our common stock on the NASDAQ Capital Market. We and the sales agent may each terminate the sales agreement at any time upon 10 days prior notice.
This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy
of the sales agreement is filed with the SEC and incorporated by reference into the registration statement of which this prospectus forms a part. See Where You Can Find More Information below.
- 12 -
LEGAL MATTERS
The validity of the securities that may be offered hereby will be passed upon for us by Choate, Hall & Stewart LLP. LeClairRyan, A
Professional Corporation, New York, New York, is counsel for MLV & Co. LLC in connection with this offering.
- 13 -
EXPERTS
The consolidated financial statements of Agenus Inc., as of December 31, 2013 and 2012, and for each of the years in the three-year
period ended December 31, 2013, and managements assessment of the effectiveness of internal control over financial reporting as of December 31, 2013 have been incorporated by reference herein and in the registration statement in
reliance upon the reports of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
The audited historical financial statements of 4-Antibody AG, incorporated by reference into our Current Report on Form 8-K filed
February 13, 2014 (as amended by our Current Report on Form 8-K/A filed April 29, 2014), have been incorporated by reference herein in reliance on the report of Ernst & Young Ltd, independent auditors to 4-Antibody AG, given on
the authority of such firm as experts in accounting and auditing.
- 14 -
WHERE YOU CAN FIND MORE INFORMATION
Agenus Inc. is subject to the information requirements of the Securities Exchange Act of 1934, as amended, and files annual, quarterly and
special reports, proxy statements and other information with the SEC. You may read and copy any materials we file with the SEC at the Public Reference Room of the SEC at Room 1580, 100 F Street, N.E., Washington, D.C. 20549. You may obtain
information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, we file many of our documents electronically with the SEC, and you may access those documents over the Internet. The SEC maintains a web
site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of the SECs website is http://www.sec.gov. Documents we have filed with the SEC are also
available on our website through the investor link at www.agenusbio.com. Information contained on our web site does not constitute a part of this prospectus and is not incorporated by reference herein.
- 15 -
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
This prospectus is part of a registration statement on Form S-3 filed by us with the SEC. This prospectus does not contain all of the
information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Statements contained in this prospectus or the documents incorporated by reference into this prospectus
as to the contents of any contract or other document referred to are not necessarily complete and in each instance reference is made to the copy of that contract or other document filed with the SEC. For further information about us and the
securities offered by this prospectus, we refer you to the registration statement and its exhibits and schedules which may be obtained as described herein.
The SEC allows us to incorporate by reference in this prospectus the information we file with the SEC. This helps us disclose
certain important information to you by referring you to the documents we file. The information we incorporate by reference is an important part of this prospectus. Because we are incorporating by reference future filings with the SEC, this
prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to
determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. We incorporate by reference each of the documents listed below.
|
|
|
our Annual Report on Form 10-K for the year ended December 31, 2013 (File No. 000-29089); |
|
|
|
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 (File No. 000-29089); |
|
|
|
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 (File No. 000-29089); |
|
|
|
our Current Reports on Form 8-K filed on July 24, 2014, July 1, 2014, June 30, 2014, June 27, 2014, June 16, 2014, April 28, 2014, April 25,
2014, April 2, 2014, March 20, 2014, March 5, 2014, February 21, 2014, February 13, 2014 (as amended by our Current Report on Form 8-K/A filed on April 29, 2014), February 6,
2014, February 4, 2014, January 21, 2014, January 14, 2014 and January 13, 2014 (except, with respect to each of the foregoing, for portions of such reports which were deemed to be furnished and not filed) (File
No. 000-29089); |
|
|
|
our Proxy Statement on Schedule 14A filed with the SEC on March 10, 2014 (File No. 000-29089); and |
|
|
|
the description of our common stock contained in our registration statement on Form 8-A filed under the Securities Exchange Act of 1934, as amended (the Exchange Act) on January 24, 2000, including any
amendment or reports filed for the purpose of updating such descriptions (File No. 000-29089). |
We will provide each person
to whom this prospectus is delivered a copy of all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus. You may obtain copies of these filings, at no cost, through the
Investor section of our website (www.agenusbio.com), and you may request copies of these filings, at no cost, by writing or telephoning us at:
Agenus Inc.
Attention: Secretary
3 Forbes Road
Lexington, MA
02421
Telephone: (781) 674-4400
The information contained on our website is not a part of this prospectus.
- 16 -
10,000,000 Shares of Common Stock
PROSPECTUS
, 2014
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth the various expenses in connection with the registration of the securities offered hereby. Agenus Inc. will bear
all of these expenses. All amounts are estimated except for the SEC registration fee:
|
|
|
|
|
Item |
|
Amount |
|
SEC registration fee |
|
$ |
17,430.00 |
|
Legal fees and expenses |
|
|
|
|
Accounting fees and expenses |
|
|
|
|
Printing and related expenses |
|
|
|
|
Miscellaneous |
|
|
|
|
Total |
|
$ |
* |
|
|
|
|
|
|
* |
The amount of securities and number of offerings are indeterminable and the expenses cannot be estimated at this time. |
Item 15. Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation Law permits, in general, a Delaware corporation to indemnify any person who was or is a
party to any proceeding (other than an action by, or in the right of, the corporation) by reason of the fact that he or she is or was a director or officer of the corporation, or served another business enterprise in any capacity at the request of
the corporation, against liability incurred in connection with such proceeding, including the expenses (including attorneys fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such
proceeding, if such person acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, in criminal actions or proceedings, additionally had no reasonable cause to believe
that his or her conduct was unlawful. A Delaware corporations power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of expenses (including attorneys fees) actually and
reasonably incurred by the person in connection with the defense or settlement of the action or suit, provided that no indemnification shall be provided in such actions in the event of any adjudication of negligence or misconduct in the performance
of such persons duties to the corporation, unless a court believes that in light of all the circumstances indemnification should apply. Section 145 of the Delaware General Corporation Law also permits, in general, a Delaware corporation
to purchase and maintain insurance on behalf of any person who is or was a director or officer of the corporation, or served another entity in any capacity at the request of the corporation, against liability incurred by such person in such
capacity, whether or not the corporation would have the power to indemnify such person against such liability.
We have entered into
indemnification agreements with each of our directors and certain executive officers and have obtained insurance covering our directors and officers against losses and insuring us against certain of our obligations to indemnify our directors and
officers.
Our Fifth Amended and Restated By-Laws provide that we shall indemnify each of our directors and officers, to the maximum
extent permitted from time to time by law, against all expenses (including attorneys fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by reason of the fact that he or she is a director or officer.
This right of indemnification conferred in our Fifth Amended and Restated By-Laws is not exclusive of any other right.
II-1
In addition, as permitted by Section 102 of the Delaware General Corporation Law, our
Amended and Restated Certificate of Incorporation includes a provision that eliminates the personal liability of our directors for monetary damages for breach of their fiduciary duty as directors except for liability (i) for any breach of the
directors duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General
Corporation Law, or (iv) for any transaction from which the director derived an improper personal benefit.
These indemnification
provisions may be sufficiently broad to permit indemnification of our directors and officers for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.
Item 16. Exhibits
The following Exhibits are filed herewith or incorporated herein by reference:
|
|
|
|
|
1.1 |
|
Form of Underwriting Agreement or Purchase Agreement.* |
|
|
1.2 |
|
At Market Issuance Sales Agreement with MLV & Co. LLC. Filed herewith. |
|
|
3.1 |
|
Amended and Restated Certificate of Incorporation of Antigenics Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on June 10, 2002 and incorporated herein by reference. |
|
|
3.1.1 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Antigenics Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on June 11, 2007 and incorporated herein by
reference. |
|
|
3.1.2 |
|
Certificate of Ownership and Merger changing the name of the corporation to Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by
reference. |
|
|
3.1.3 |
|
Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on September 30, 2011 and incorporated herein
by reference. |
|
|
3.1.4 |
|
Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q (File No. 000-02089) filed on November 7, 2012 and incorporated herein
by reference. |
|
|
3.1.5 |
|
Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on April 25, 2014 and incorporated by
reference herein. |
|
|
3.2 |
|
Fifth Amended and Restated By-laws of Agenus Inc. filed as Exhibit 3.2 to our Annual Report on Form 10-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by reference. |
|
|
3.3 |
|
Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of Agenus Inc. filed with the Secretary of State of the State of Delaware on September 24, 2003. Filed as Exhibit 3.1 to our Current
Report on Form 8-K (File No. 000-29089) filed on September 25, 2003 and incorporated herein by reference. |
|
|
3.4 |
|
Certificate of Designations, Preferences and Rights of the Class B Convertible Preferred Stock of Agenus Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on September 5, 2007 and incorporated
herein by reference. |
|
|
3.5 |
|
Certificate of Designations, Preferences and Rights of the Series A-1 Convertible Preferred Stock of Agenus Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on February 5. 2013 and incorporated
herein by reference. |
II-2
|
|
|
|
|
4.1 |
|
Form of Indenture. Filed as Exhibit 4.14 to Amendment No. 1 to our registration statement on Form S-3 dated July 23, 2002 (File No. 333-90380) and incorporated herein by
reference. |
|
|
4.2 |
|
Form of Common Stock Certificate. Filed as Exhibit 4.1 to our Current Report on Form 8-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by reference. |
|
|
4.3 |
|
Securities Purchase Agreement by and between Agenus Inc. and the investors identified on Schedule I attached to the agreement, dated January 9, 2008. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) filed
on January 11, 2008 and incorporated herein by reference. |
|
|
4.4 |
|
Securities Purchase Agreement dated April 8, 2008. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) filed on April 10, 2008 and incorporated herein by reference. |
|
|
4.5 |
|
Securities Purchase Agreement dated as of July 30, 2009 by and among Agenus Inc. and the investors listed on the Schedule of Buyers thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) filed on
August 3, 2009 and incorporated herein by reference. |
|
|
4.6 |
|
Specimen certificate for shares of Preferred Stock.* |
|
|
4.7 |
|
Form of Depositary Shares.* |
|
|
4.8 |
|
Form of Warrant.* |
|
|
4.9 |
|
Form of Stock Purchase Contract.* |
|
|
4.10 |
|
Form of Senior Debt Security.* |
|
|
4.11 |
|
Form of Subordinated Debt Security.* |
|
|
4.12 |
|
Form of Unit Agreement.* |
|
|
5.1 |
|
Opinion of Choate, Hall & Stewart LLP. |
|
|
12.1 |
|
Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Earnings to Combined Fixed Charges and Preferred Stock Dividends. |
|
|
23.1 |
|
Consent of Choate, Hall & Stewart LLP (included in Exhibit 5.1). |
|
|
23.2 |
|
Consent of KPMG LLP, an independent registered public accounting firm. |
|
|
23.3 |
|
Consents of Ernst & Young Ltd, independent auditors to 4-Antibody AG. |
|
|
24.1 |
|
Power of Attorney (included in the signature page to this Registration Statement). |
|
|
25.1 |
|
Form T-1 Statement of Eligibility of Trustee under Indenture for Senior Debt Securities under the Trust Indenture Act of 1939, as amended.** |
|
|
25.2 |
|
Form T-1 Statement of Eligibility of Trustee under Indenture for Subordinated Debt Securities under the Trust Indenture Act of 1939, as amended.** |
* |
To be filed, if necessary, by post-effective amendment to this registration statement or as an exhibit to a current report of the registrant on Form 8-K and incorporated herein by reference. |
** |
To be incorporated herein by reference from a subsequent filing in accordance with Section 305(b)(2) of the Trust Indenture Act of 1939. |
Item 17. Undertakings
(a) |
The undersigned registrant hereby undertakes: |
|
(1) |
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
|
(i) |
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
II-3
|
(ii) |
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than a 20 percent change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective registration statement; |
|
(iii) |
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in this registration statement;
|
Provided, however, That Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the
registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to
section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the
registration statement.
|
(2) |
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
|
(3) |
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
|
(4) |
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
|
(i) |
If the registrant is relying on Rule 430B: |
|
(A) |
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration
statement; and |
|
(B) |
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415 (a)(1)(i),
(vii) or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of
prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date
an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof. |
Provided, however, that no statement made in a
registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such effective date.
II-4
|
(5) |
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: |
The undersigned registrant undertakes that in an offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser:
|
(i) |
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
|
(ii) |
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
|
(iii) |
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
(iv) |
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) |
The undersigned registrant hereby further undertakes that, for the purposes of determining any liability under the Securities Act of 1933, each filing of the registrants annual report pursuant to section 13(a) or
section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plans annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(c) |
The undersigned registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or given, the latest annual report to security holders that is
incorporated by reference in the prospectus and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934; and, where interim financial information required to be presented by
Article 3 of Regulation S-X is not set forth in the prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the last quarterly report that is specifically incorporated by reference in the
prospectus to provide such interim financial information. |
(d) |
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. |
II-5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Lexington, Commonwealth of Massachusetts, on this 10th day of
October, 2014.
|
|
|
AGENUS INC. |
|
|
By: |
|
/s/ Garo H. Armen |
|
|
Garo H. Armen |
|
|
Chief Executive Officer and Chairman of the Board |
II-6
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Garo H. Armen, Karen
Valentine and Christine M. Klaskin, jointly and severally, his or her true and lawful attorneys-in-fact and agents with full powers of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all supplements
amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below on the dates indicated by the
following persons in the capacities indicated.
|
|
|
|
|
SIGNATURE |
|
TITLE |
|
DATE |
|
|
|
/s/ Garo H. Armen
Garo H. Armen |
|
Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) |
|
October 10, 2014 |
|
|
|
/s/ Christine M. Klaskin
Christine M. Klaskin |
|
Vice President, Finance (Principal Accounting Officer and Principal Financial Officer) |
|
October 10, 2014 |
|
|
|
/s/ Brian Corvese
Brian Corvese |
|
Director |
|
October 10, 2014 |
|
|
|
/s/ Tom Dechaene
Tom Dechaene |
|
Director |
|
October 10, 2014 |
|
|
|
/s/ Wadih Jordan
Wadih Jordan |
|
Director |
|
October 10, 2014 |
|
|
|
/s/ Shahzad Malik
Shahzad Malik |
|
Director |
|
October 10, 2014 |
|
|
|
/s/ Shalini Sharp
Shalini Sharp |
|
Director |
|
October 10, 2014 |
|
|
|
/s/ Timothy R. Wright
Timothy R. Wright |
|
Director |
|
October 10, 2014 |
II-7
INDEX TO EXHIBITS
|
|
|
|
|
1.1 |
|
Form of Underwriting Agreement or Purchase Agreement.* |
|
|
1.2 |
|
At Market Issuance Sales Agreement with MLV & Co. LLC. Filed herewith. |
|
|
3.1 |
|
Amended and Restated Certificate of Incorporation of Antigenics Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on June 10, 2002 and incorporated herein by reference. |
|
|
3.1.1 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Antigenics Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on June 11, 2007 and incorporated herein by
reference. |
|
|
3.1.2 |
|
Certificate of Ownership and Merger changing the name of the corporation to Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by
reference. |
|
|
3.1.3 |
|
Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on September 30, 2011 and incorporated herein
by reference. |
|
|
3.1.4 |
|
Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q (File No. 000-02089) filed on November 7, 2012 and incorporated herein
by reference. |
|
|
3.1.5 |
|
Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of Agenus Inc. filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on April 25, 2014 and incorporated by
reference herein. |
|
|
3.2 |
|
Fifth Amended and Restated By-laws of Agenus Inc. filed as Exhibit 3.2 to our Annual Report on Form 10-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by reference. |
|
|
3.3 |
|
Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of Agenus Inc. filed with the Secretary of State of the State of Delaware on September 24, 2003. Filed as Exhibit 3.1 to our Current
Report on Form 8-K (File No. 000-29089) filed on September 25, 2003 and incorporated herein by reference. |
|
|
3.4 |
|
Certificate of Designations, Preferences and Rights of the Class B Convertible Preferred Stock of Agenus Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on September 5, 2007 and incorporated
herein by reference. |
|
|
3.5 |
|
Certificate of Designations, Preferences and Rights of the Series A-1 Convertible Preferred Stock of Agenus Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) filed on February 5. 2013 and incorporated
herein by reference. |
|
|
4.1 |
|
Form of Indenture. Filed as Exhibit 4.14 to Amendment No. 1 to our registration statement on Form S-3 dated July 23, 2002 (File No. 333-90380) and incorporated herein by reference. |
|
|
4.2 |
|
Form of Common Stock Certificate. Filed as Exhibit 4.1 to our Current Report on Form 8-K (File No. 000-29089) filed on January 6, 2011 and incorporated herein by reference. |
|
|
4.3 |
|
Securities Purchase Agreement by and between Agenus Inc. and the investors identified on Schedule I attached to the agreement, dated January 9, 2008. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089)
filed on January 11, 2008 and incorporated herein by reference. |
|
|
4.4 |
|
Securities Purchase Agreement dated April 8, 2008. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) filed on April 10, 2008 and incorporated herein by reference. |
|
|
4.5 |
|
Securities Purchase Agreement dated as of July 30, 2009 by and among Agenus Inc. and the investors listed on the Schedule of Buyers thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) filed on
August 3, 2009 and incorporated herein by reference. |
II-8
|
|
|
|
|
4.6 |
|
Specimen certificate for shares of Preferred Stock.* |
|
|
4.7 |
|
Form of Depositary Shares.* |
|
|
4.8 |
|
Form of Warrant.* |
|
|
4.9 |
|
Form of Stock Purchase Contract.* |
|
|
4.10 |
|
Form of Senior Debt Security.* |
|
|
4.11 |
|
Form of Subordinated Debt Security.* |
|
|
4.12 |
|
Form of Unit Agreement.* |
|
|
5.1 |
|
Opinion of Choate, Hall & Stewart LLP. |
|
|
12.1 |
|
Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Earnings to Combined Fixed Charges and Preferred Stock Dividends. |
|
|
23.1 |
|
Consent of Choate, Hall & Stewart LLP (included in Exhibit 5.1). |
|
|
23.2 |
|
Consent of KPMG LLP, an independent registered public accounting firm. |
|
|
23.3 |
|
Consents of Ernst & Young Ltd, independent auditors to 4-Antibody AG. |
|
|
24.1 |
|
Power of Attorney (included in the signature page to this Registration Statement). |
|
|
25.1 |
|
Form T-1 Statement of Eligibility of Trustee under Indenture for Senior Debt Securities under the Trust Indenture Act of 1939, as amended.** |
|
|
25.2 |
|
Form T-1 Statement of Eligibility of Trustee under Indenture for Subordinated Debt Securities under the Trust Indenture Act of 1939, as amended.** |
* |
To be filed, if necessary, by post-effective amendment to this registration statement or as an exhibit to a current report of the registrant on Form 8-K and incorporated herein by reference. |
** |
To be incorporated herein by reference from a subsequent filing in accordance with Section 305(b)(2) of the Trust Indenture Act of 1939. |
II-9
Exhibit 1.2
AGENUS INC.
Common
Stock (par value 0.01)
AT MARKET ISSUANCE SALES AGREEMENT
October 10, 2014
MLV & Co. LLC
1251 Avenue of the Americas, 41st Floor
New York, NY 10020
Ladies and Gentlemen:
Agenus Inc., a Delaware corporation (the Company), confirms its agreement with MLV & Co. LLC, a Delaware limited
liability company (MLV or the Agent), as follows:
1. Issuance and Sale of Placement Shares.
The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent, shares (the Placement Shares) of the
Companys common stock, par value $0.01 per share (the Common Stock); provided however, that in no event shall the Company issue or sell through MLV such number of Placement Shares that (a) exceeds the number of shares
of Common Stock registered on the Registration Statement (as defined below) pursuant to which the offering will be made, or (b) exceeds the number of authorized but unissued shares of Common Stock (the lesser of (a) and (b), the
Maximum Amount). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1 on the number of Placement Shares issued and sold under
this Agreement shall be the sole responsibility of the Company and that MLV shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration
Statement (as defined below) filed by the Company and to be declared effective by the Securities and Exchange Commission (the Commission), although nothing in this Agreement shall be construed as requiring the Company to use the
Registration Statement to issue any Placement Shares.
The Company has filed, in accordance with the provisions of the Securities Act of
1933, as amended (the Securities Act), and the rules and regulations thereunder (the Rules and Regulations), with the Commission a registration statement on Form S-3,
including one or more base prospectuses, relating to certain securities, including the Placement Shares, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in
accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the Exchange Act). The Company will, if necessary, prepare a prospectus supplement
to the base prospectus included as part of such registration statement specifically relating to the Placement Shares (the Prospectus Supplement). The Company will furnish to MLV, for use by MLV, copies of the base prospectus
included as part of such registration statement, supplemented, if at all, by the Prospectus Supplement. Except where the context otherwise requires, such registration statement, and documents filed as part thereof or incorporated by reference
therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act and also including any other registration statement filed pursuant to
Rule 462(b) under the Securities Act, as well as any comparable successor registration statement filed by the Company for the sale of its Common Stock, including the Placement Shares, collectively, are herein called the Registration
Statement. The base prospectus specifically relating to the Placement Shares and identifying the Agent therein, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by
the Prospectus Supplement or any other final prospectus relating to a Placement (as defined below), in the form in which such base prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to
Rule 424(b) under the Securities Act is herein called the Prospectus. The parties acknowledge and agree that
the Company intends to include a number of additional base prospectuses, other than the Prospectus, in the Registration Statement, and that all references to the Prospectus herein are references
only to the Prospectus and not to any other base prospectuses included in the Registration Statement. Unless the context otherwise requires, any reference herein to the Registration Statement or the Prospectus shall be deemed to refer to and include
any amendment or supplement thereto and to refer to and include the documents incorporated or deemed to be incorporated by referenced therein. For purposes of this Agreement, all references to the Registration Statement, the Prospectus and to any
amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System (EDGAR).
2. Placements. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a Placement),
it will notify MLV by email notice (or other method mutually agreed to in writing by the parties) of the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement
Shares that may be sold in any one day and any minimum price below which sales may not be made (a Placement Notice), the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of the
individuals from the Company set forth on Schedule 3 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from MLV set forth on Schedule 3, as such Schedule 3 may
be amended from time to time. The Placement Notice shall be effective unless and until (i) MLV declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares thereunder
have been sold, (iii) the Company suspends or terminates the Placement Notice or (iv) the Agreement has been terminated under the provisions of Section 11. The amount of any discount, commission or other compensation to be paid by the
Company to MLV in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company nor MLV will have any obligation whatsoever
with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to MLV and MLV does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein
and herein. In the event of a conflict between the terms of Section 2 or 3 of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.
3. Sale of Placement Shares by the Agent. Subject to the terms and conditions of this Agreement, for the period specified in the
Placement Notice, the Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement
Notice. The Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) next following the Trading Day on which the Agent has made sales of Placement Shares hereunder setting forth the
number of Placement Shares sold on such day, the compensation payable by the Company to the Agent with respect to such sales pursuant to Section 2, and the Net Proceeds (as defined below) payable to the Company, with an itemization of
deductions made by the Agent (as set forth in Section 5(a)) from gross proceeds for the Placement Shares that they receive from such sales. The Agent agrees that all sales of Placement Shares will be made only by methods deemed to be an
at the market offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on the NASDAQ Capital Market (the Exchange) or on any other existing trading market for the
Common Stock. Unless otherwise agreed to between the Company and the Agent, the Agent acknowledges and agrees that all sales of Placement Shares will be made at prevailing market prices in ordinary brokerage transactions open to all market
participants. The Agent may only sell Placement Shares in negotiated transactions with the prior express written consent of the Company which, if the Placement Notice provided for such negotiated transactions, may include the Acceptance. The Company
acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, and (ii) the Agent will not incur any liability or obligation to the Company or any other person or entity if it does
not sell Placement Shares for any reason other than a failure by it to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares as required under this Section 3. For the
purposes hereof, Trading Day means any day on which Common Stock is purchased and sold on the principal market on which the Common Stock is listed or quoted.
4. Suspension of Sales. The Company or MLV may, upon notice to the other party in writing
(including by email correspondence to an individual set forth on Schedule 3 if receipt of such correspondence is actually acknowledged by the individual to whom the notice is sent, other than via auto-reply)
or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement Shares; provided, however,
that such suspension shall not affect or impair any partys obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this Section 4 shall be
effective against any other party unless it is made to one of the individuals named on Schedule 3 hereto, as such Schedule may be amended from time to time.
5. Settlement.
(a) Settlement of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales
of Placement Shares will occur on the third Business Day (or such earlier day as is industry practice for regular-way trading) (each, a Settlement Date) following the respective Point of
Sale (as defined below). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the Net Proceeds) will be equal to the aggregate sales price received by the Agent
at which such Placement Shares were sold, after deduction for (i) the Agents commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any other undisputed amounts
due and payable by the Company to the Agent hereunder pursuant to Section 7(g) (Expenses).
(b) Delivery of
Placement Shares. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold by crediting the Agents or its designees account (provided the Agent
shall have given the Company written notice of such designee at least one Business Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be
mutually agreed upon by the parties hereto, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an
account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date, then in addition to
and in no way limiting the rights and obligations set forth in Section 9(a) (Indemnification) hereto, it will hold the Agent harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred,
arising out of or in connection with such default by the Company; provided, however, that the Company shall not be obligated to so indemnify and reimburse the Agent if the Placement Shares are not delivered due to (1) a suspension
or material limitation in trading in securities generally on the New York Stock Exchange or the Exchange; (2) a general moratorium on commercial banking activities declared by either federal or New York State authorities or a material
disruption in commercial banking or securities settlement or clearance services in the United States; (3) an outbreak or escalation of hostilities or acts of terrorism involving the United States or a declaration by the United States of a
national emergency or war; or (4) any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere.
6. Representations and Warranties of the Company. The Company represents and warrants to, and agrees with, the Agent that as of the
date of this Agreement and as of each Representation Date (as defined in Section 7(m) below) on which a certificate is required to be delivered pursuant to Section 7(m) of this Agreement, as the case may be:
(a) The Registration Statement has been prepared by the Company in conformity with the requirements of the Securities Act, and
the Rules and Regulations. Prior to the time of the delivery of the first Placement Notice, the Registration Statement will have been filed with the Commission and will have been declared effective under the Securities Act. Prior to the time of the
delivery of the first Placement Notice hereunder, no stop order of the Commission preventing or suspending any Prospectus or the effectiveness of the Registration Statement will have been issued, and no proceeding for that purpose will have been
instituted by the Commission. The Company and the transactions contemplated by this Agreement meet the
requirements and comply with the conditions for the use of Form S-3. The Registration Statement and the offer and sale of Placement Shares as
contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. As used in this Agreement:
(i) Effective Date means any date as of which any part of the Registration Statement becomes, or is deemed
to have become, effective under the Securities Act in accordance with the Rules and Regulations;
(ii) Issuer Free
Writing Prospectus means each issuer free writing prospectus (as defined in Rule 405 of the Rules and Regulations) prepared by or on behalf of the Company or used or referred to by the Company in connection with the
offering of the Placement Shares;
(iii) Point of Sale means, for a Placement, the time at which an
acquiror of Placement Shares entered into a contract, binding on such acquiror, to acquire such Placement Shares;
(b) The
Company was not at the time of the initial filing of the Registration Statement, has not been since the date of such filing, and will not be on any Settlement Date, an ineligible issuer (as defined in Rule 405 under the Securities
Act). The Company has been since the time of the initial filing of the Registration Statement and continues to be eligible to use Form S-3 for the offering of the Placement Shares.
(c) The Registration Statement, when it becomes effective, and the Prospectus, and any amendment or supplement thereto, on the
date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements of the Securities Act and the Rules and Regulations. The documents incorporated by reference in the Prospectus conformed
and will conform when filed with the Commission, to the requirements of the Exchange Act or the Securities Act, as applicable, and the Rules and Regulations.
(d) The Registration Statement will not, as of the Effective Date, contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that the Company makes no warranty or representation with respect to any statement contained in the
Registration Statement in reliance upon and in conformity with information furnished in writing by the Agent to the Company expressly for use in the Registration Statement.
(e) The Prospectus will not, as of its date, the date of any supplement thereto, each Settlement Date and each Point of Sale
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made or prevailing at such future
time, not misleading; provided, however, that the Company makes no warranty or representation with respect to any statement contained in the Prospectus in reliance upon and in conformity with information furnished in writing from the
Agent to the Company expressly for use in the Prospectus.
(f) The documents incorporated by reference in the Prospectus
did not, and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or
necessary to make the statements in such document, in light of the circumstances under which they were made or prevailing at such future time, not misleading.
(g) Each Issuer Free Writing Prospectus, if any, did not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representation or warranty
with respect to any statement contained in the Issuer Free Writing Prospectus in reliance upon and in conformity with information concerning the Agent and furnished in writing by the Agent to the Company expressly for use in the Issuer Free Writing
Prospectus.
(h) Each Issuer Free Writing Prospectus, if any, conformed or will conform in all material respects to the
requirements of the Securities Act and the Rules and Regulations on the date of first use, and the Company has complied or will comply with any filing requirements applicable to such Issuer Free Writing
Prospectus pursuant to the Rules and Regulations. Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of any Placement for which such
Issuer Free Writing Prospectus is used, will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference
therein that has not been superseded or modified. The Company has not made any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus without the prior written consent of the Agent. The Company has retained in
accordance with the Rules and Regulations all Issuer Free Writing Prospectuses that were not required to be filed pursuant to the Rules and Regulations.
(i) The Company is, and at each Settlement Date will be, duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Company (i) has, and at each Settlement Date will have, full power and authority to conduct all the activities conducted by it, to own or lease all the assets owned or leased by it and to conduct its business as
described in the Registration Statement and the Prospectus and (ii) is, and at each Settlement Date will be, duly licensed or qualified to do business and in good standing as a foreign organization in all jurisdictions in which the nature of
the activities conducted by it or the character of the assets owned or leased by it makes such licensing or qualification necessary; except, in each case, where the failure to be so qualified or in good standing or have such power or authority would
not or would not reasonably be expected to, individually or in the aggregate, have a material adverse effect on the business, financial position, stockholders equity or results of operations of the Company and its subsidiaries, taken as a
whole (a Material Adverse Effect). Complete and correct copies of the articles or certificate of incorporation and of the bylaws of the Company and all amendments thereto have been delivered or made available to the Agent, and no
changes therein will be made in the period beginning three days prior to the Acceptance of a Placement Notice and ending on the Settlement Date with respect to such Placement unless such amendments have been delivered to the Agent not less than five
days prior to such Settlement Date. None of the Company or any Subsidiary (as defined below) is in material violation of any provision of its organizational or governing documents.
(j) Each subsidiary of the Company (each a Subsidiary and collectively, the Subsidiaries)
that is a significant subsidiary as such term is defined in Rule 1-02(w) of Regulation S-X under the Securities Act (each a Significant
Subsidiary and collectively, the Significant Subsidiaries) has been duly incorporated or organized and is validly existing as a corporation, limited liability company or limited partnership, as the case may be, in good
standing under the laws of the jurisdiction of its incorporation or organization, has corporate power and authority to own, lease and operate its properties and conduct its business as described in the Prospectus and is duly qualified as a foreign
corporation, limited liability company or limited partnership, as the case may be, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business, except where the failure to so qualify would not have a Material Adverse Effect; all of the issued and outstanding capital stock of, or other ownership interests in, each such Significant Subsidiary has been duly
authorized and validly issued, is fully paid and non-assessable and, except for directors qualifying shares or as otherwise set forth in the Registration Statement, is owned by the Company, directly or
through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity; and Exhibit 21 to the Companys Annual Report on Form 10-K for the year ended December 31, 2013 is an accurate and
complete list of the Significant Subsidiaries.
(k) The issued and outstanding shares of capital stock of the Company have
been validly issued, are fully paid and non-assessable and, other than as set forth in the Registration Statement, are not subject to any preemptive rights, rights of first refusal or similar rights. The
Company has an authorized, issued and outstanding capitalization as set forth in the Prospectus as of the dates referred to therein. The descriptions of the securities of the Company in the Registration Statement and the Prospectus are, and at each
Settlement Date will be, complete and accurate in all material respects. Except as set forth in the Registration Statement and the Prospectus, the Company does not have outstanding any rights (other than stock options or other equity awards under
the Companys equity incentive and stock purchase plans) or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.
(l) The Company has full legal right, power and authority to enter into this
Agreement and perform the transactions contemplated hereby. This Agreement has been authorized and validly executed and delivered by the Company and is a legal, valid and binding agreement of the Company enforceable against the Company in accordance
with its respective terms, subject to the effect of applicable bankruptcy, insolvency or similar laws affecting creditors rights generally and equitable principles of general applicability.
(m) The issuance and sale of the Placement Shares have been duly authorized by the Company, and the Placement Shares, when
issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and non-assessable and will not be subject to preemptive or similar rights. The holders of the Placement
Shares will not be subject to personal liability solely by reason of being such holders. The Placement Shares, when issued, will conform in all material respects to the description thereof set forth in or incorporated into the Prospectus.
(n) The financial statements and the related notes included in the Registration Statement and the Prospectus present fairly, in
all material respects, the financial condition of the Company as of the dates thereof and the results of operations and cash flows at the dates and for the periods covered thereby in conformity with generally accepted accounting principles
(GAAP) applied on a consistent basis for the periods involved. Any pro forma financial statements or data included or incorporated by reference in the Registration Statement and the Prospectus comply with the requirements of Regulation S-X of the Securities Act, including, without limitation, Article 11 thereof, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable, the pro
forma adjustments used therein are appropriate to give effect to the circumstances referred to therein and the pro forma adjustments have been properly applied to the historical amounts in the compilation of those statements and data. No other
financial statements or schedules of the Company or any other entity are required by the Securities Act or the Rules and Regulations to be included in the Registration Statement or the Prospectus. All disclosures contained in the Registration
Statement or the Prospectus regarding non-GAAP financial measures (as such term is defined by the Rules and Regulations) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The Company does not have any material liabilities or obligations, direct or contingent (including any
off-balance sheet obligations and any variable interest entities within the meaning of Financial Accounting Standards Board Interpretation No. 46), not disclosed in the Registration Statement
or the Prospectus.
(o) The independent registered public accounting firm whose report on the consolidated financial
statements and schedules of the Company and the Subsidiaries is incorporated by reference in the Registration Statement and the Prospectus is a registered independent public accountant with respect to the Company as required by the Securities Act
and the Rules and Regulations and by the rules of the Public Company Accounting Oversight Board. The financial statements of the Company and the related notes and schedules included in the Registration Statement and the Prospectus have been prepared
in conformity with the requirements of the Securities Act and the Rules and Regulations and present fairly the information shown therein.
(p) Except as set forth in the Registration Statement and the Prospectus, there is and has been no failure on the part of the
Company, or to its knowledge after due inquiry, any of the Companys directors or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes Oxley Act of 2002 and the rules and regulations promulgated
therewith (the Sarbanes Oxley Act), including without limitation Section 402 related to loans and Sections 302 and 906 related to certifications.
(q) Except as set forth in the Registration Statement and the Prospectus, the Company maintains disclosure controls and
procedures and internal controls over financial reporting (each as defined in Rule 13a-15 under the Exchange Act) that comply with the requirements of the Exchange Act. The Companys certifying
officers have evaluated the effectiveness of the Companys disclosure controls and procedures as of the end of the periods covered by the Form 10-K for the year ended December 31, 2013, each Form 10-Q filed with the Commission in 2014 and each Form 10-Q and Form 10-K filed with the Commission during the term
of this Agreement (each such date, an Evaluation Date). The Company presented in its Form 10-K for the year ended December 31, 2013 and in each
Form 10-Q filed in 2014 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the applicable Evaluation Date.
(r) Except as set forth in the Registration Statement or the Prospectus, since
the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement or the Prospectus, (i) there has not been any change in the capital stock of the Company or long term debt of
the Company or any issuance of stock options or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, other than would not have a Material Adverse Effect and
(ii) neither the Company nor any Subsidiary has sustained any material loss or material interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute
or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement or the Prospectus.
(s) For each Placement, from the Point of Sale until the Settlement Date, neither the Company nor any Subsidiary will enter
into any transaction or agreement or series of transactions or agreements, not in the ordinary course of business, that is material to the Company or incur any liability or obligation, direct or contingent, not in the ordinary course of business,
that is material to the Company, in each case to the extent such transaction, agreement, series of transactions or agreements, liability or obligation would make the statements in the Registration Statement or the Prospectus contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
(t) Except as set forth in the Registration Statement or the Prospectus, the Company and each Subsidiary has good and valid
title in fee simple to all items of real property and good and valid title to all tangible personal property described in the Registration Statement or the Prospectus as being owned by them that are material to the businesses of the Company or such
Subsidiary, in each case free and clear of all liens, encumbrances and claims except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company or such Subsidiary or (ii) the loss
of which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration Statement or the Prospectus as being leased by the Company or a Subsidiary or that is
material to the business of the Company or such Subsidiary is held by it or such Subsidiary under valid, existing and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of such
property by the Company or such Subsidiary or (B) the loss of which would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect.
(u) The Company is not, nor upon completion of the transactions contemplated herein will it be, an investment
company or promoter or principal underwriter for an investment company, as such terms are defined in the Investment Company Act of 1940, as amended.
(v) Except as set forth in the Registration Statement or the Prospectus, there are no legal, governmental or regulatory
actions, suits or proceedings pending, nor, to the Companys knowledge, any legal, governmental or regulatory investigations, to which the Company or a Subsidiary is a party or to which any property of the Company or a Subsidiary is the subject
that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations under this Agreement (collectively, the
Actions); to the Companys knowledge, no such Actions are threatened by any governmental or regulatory authority or threatened by others; and there are no current or pending legal, governmental or regulatory investigations,
actions, suits or proceedings that are required under the Securities Act to be described in the Prospectus that are not so described.
(w) Except as set forth in the Registration Statement or the Prospectus, the Company and each Subsidiary has, and at each
Settlement Date will have, (i) all governmental licenses, permits, consents, orders, approvals and other authorizations necessary to carry on its respective business as presently conducted except where the failure to have such governmental
licenses, permits, consents, orders, approvals and other authorizations would not have a Material Adverse Effect, (ii) complied with all laws, regulations and orders applicable to either it or its business, except where the failure to so comply
would not have a Material Adverse Effect, and (iii) performed all its obligations required to be performed, and is not, and at each Settlement Date will not be, in default, under any indenture, mortgage, deed of trust, voting trust
agreement, loan agreement, bond, debenture, note agreement, lease, contract or other agreement or instrument (collectively, a contract or other agreement) to which it or such
Subsidiary is a party or by which its or such Subsidiarys property is bound or subject, except where such nonperformance or default would not have a Material Adverse Effect, and, to the Companys knowledge, no other party under any
material contract or other agreement to which it or a Subsidiary is a party is in default in any respect thereunder where such default would have a Material Adverse Effect.
(x) All consents, authorizations, approvals and orders required for the execution and delivery of this Agreement have been
obtained, including approval of stockholders of the Company as necessary, except such as may be required under state securities or Blue Sky Laws or the by-laws and rules of the Financial Industry Regulatory
Authority (FINRA) or the Exchange in connection with the distribution of the Placement Shares by the Agent. In accordance with FINRA Conduct Rule 5110(b)(7)(C)(i), the Common Stock has been registered with the Commission on Form
S-3 under the Securities Act pursuant to the standards for such Form S-3 in effect prior to October 21, 1992.
(y)
Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation of any of the transactions contemplated herein, nor the compliance by the Company with the terms and provisions hereof will
conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any
property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as
may have been waived and (ii) such conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x) in any violation of the provisions of the organizational or governing documents of the
Company, or (y) in any material violation of the provisions of any statute or any order, rule or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or other government body having
jurisdiction over the Company.
(z) There is no document or contract of a character required to be described in the
Registration Statement or the Prospectus or to be filed as an exhibit to the Registration Statement which is not described or filed as required.
(aa) No statement, representation or warranty made by the Company in this Agreement or made in any certificate or document
required by this Agreement to be delivered to the Agent was, when made, inaccurate, untrue or incorrect in any material respect.
(bb) The Company and its directors, officers or controlling persons have not taken, directly or indirectly, any action
intended, or which might reasonably be expected, to cause or result, under the Act or otherwise, in, or which has constituted, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Common
Stock.
(cc) No holder of securities of the Company has rights to the registration of any securities of the Company as a
result of the filing of the Registration Statement or the transactions contemplated by this Agreement, except for such rights as have been waived or satisfied.
(dd) The Common Stock is currently listed on the Exchange. Except as disclosed in the Registration Statement or the Prospectus,
the Company has not, in the 12 months preceding the date hereof, received notice from the Exchange to the effect that the Company is not in compliance with the listing or maintenance requirements. Except as disclosed in the Registration Statement or
the Prospectus, the Company has no reason of which it is currently aware to believe that it will not in the foreseeable future continue to be in compliance with all such listing and maintenance requirements.
(ee) Except as disclosed in the Registration Statement or the Prospectus, neither the Company nor any Subsidiary is involved in
any material labor dispute nor is any such dispute known by the Company to be threatened.
(ff) The business and operations
of the Company and its Subsidiaries have been and are being conducted in compliance with all applicable laws, ordinances, rules, regulations, licenses, permits, approvals, plans, authorizations or requirements relating to occupational safety and
health, or pollution, or
protection of health or the environment (including, without limitation, those relating to emissions, discharges, releases or threatened releases of pollutants, contaminants or hazardous or toxic
substances, materials or wastes into ambient air, surface water, groundwater or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of chemical substances, pollutants, contaminants
or hazardous or toxic substances, materials or wastes, whether solid, gaseous or liquid in nature) of any governmental department, commission, board, bureau, agency or instrumentality of the United States, any state or political subdivision thereof,
or any foreign jurisdiction, and all applicable judicial or administrative agency or regulatory decrees, awards, judgments and orders relating thereto, except where the failure to be in such compliance will not, individually or in the aggregate,
have a Material Adverse Effect; and neither the Company nor any Subsidiary has received any notice from any governmental instrumentality or any third party alleging any material violation thereof or liability thereunder (including, without
limitation, liability for costs of investigating or remediating sites containing hazardous substances and/or damages to natural resources) that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
(gg) Except as disclosed in the Registration Statement or the Prospectus, to the Companys knowledge, (i) the Company
or any of its Subsidiaries owns or has obtained valid and enforceable licenses or options for the inventions, patent applications, patents, trademarks (both registered and unregistered), trade names, copyrights and trade secrets necessary for the
conduct of its business as currently conducted (collectively, the Intellectual Property); and (ii) (a) there are no third parties who have any ownership rights to any Intellectual Property that is owned by, or has been
licensed to, the Company or any of its Subsidiaries for the products described in the Registration Statement or the Prospectus that would preclude the Company or any of its Subsidiaries from conducting its business as currently conducted and have a
Material Adverse Effect, except for the ownership rights of the owners of the Intellectual Property licensed or optioned by the Company or such Subsidiary; (b) there are currently no sales of any products that would constitute an infringement
by third parties of any Intellectual Property owned, licensed or optioned by the Company or its Subsidiaries, which infringement would have a Material Adverse Effect; (c) there is no pending or threatened action, suit, proceeding or claim by
others challenging the rights of the Company or a Subsidiary in or to any Intellectual Property owned, licensed or optioned by the Company or such Subsidiary, other than claims which would not reasonably be expected to have a Material Adverse
Effect; (d) there is no pending or threatened action, suit, proceeding or claim by others challenging the validity or scope of any Intellectual Property owned, licensed or optioned by the Company or a Subsidiary, other than actions, suits,
proceedings and claims which would not reasonably be expected to have a Material Adverse Effect; and (e) there is no pending or threatened action, suit, proceeding or claim by others that the Company or a Subsidiary infringes or otherwise
violates any patent, trademark, copyright, trade secret or other proprietary right of others, other than actions, suits, proceedings and claims which would not reasonably be expected to have a Material Adverse Effect.
(hh) The Company has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued
all taxes shown as due thereon, and the Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which could have a Material Adverse
Effect.
(ii) On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be
paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.
(jj) The Company maintains insurance of the types and in the amounts that the Company reasonably believes is adequate for its
businesses and as is customary for companies engaged in similar businesses.
(kk) Neither the Company, nor, to the
knowledge of the Company, any director, officer, agent or employee of the Company or any of its Subsidiaries, has directly or indirectly, (i) made any unlawful contribution to any candidate for public office, or failed to disclose fully any
contribution in violation of law, (ii) made any payment to any federal or state governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments
required or permitted by the laws of the United States or any jurisdiction thereof, (iii) violated or is in violation of any provisions of the U.S. Foreign Corrupt Practices Act of 1977 or (iv) made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment.
(ll) The Company has not distributed and, prior to the later to occur of each
Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material in connection with the offering and sale of the Placement Shares other than any the Prospectus and any Issuer Free Writing
Prospectus to which the Agent has consented.
(mm) Each material employee benefit plan, within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (ERISA), that is maintained, administered or contributed to by the Company or any of its affiliates for employees or former employees of the
Company has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the
Code); no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect to any such plan excluding
transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no accumulated funding deficiency as
defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits
accrued under such plan determined using reasonable actuarial assumptions.
(nn) No relationship, direct or indirect,
exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other, which is required by the Securities Act to be disclosed in the Registration Statement or the
Prospectus and is not so disclosed.
(oo) The Company has not sold or issued any securities that would be integrated with
the offering of the Placement Shares contemplated by this Agreement pursuant to the Act, the Rules and Regulations or the interpretations thereof by the Commission.
(pp) The Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that
would give rise to a valid claim against the Company or the Agent (or any co-agent or sub-agent thereof) for a brokerage commission, finders fee or like payment in
connection with the offering and sale of the Placement Shares.
(qq) Except as disclosed in the Registration Statement or
the Prospectus, the Company is not a party to any agreement with an agent or underwriter for any other at-the-market or continuous equity transaction.
(rr) The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted
under the Securities Act and the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect; provided, that (i) no such purchases or sales shall take place while a Placement Notice
is in effect (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a riskless principal or in a similar capacity) and (ii) the Company shall not be deemed to have
authorized or consented to any such purchases or sales by the Agent.
7. Covenants of the Company. The Company covenants and agrees
with the Agent that:
(a) Registration Statement Amendments. During any period in which a Prospectus relating to any
Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), (i) the Company will notify the Agent
promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference or amendments not related to any Placement, has been filed with the Commission and/or has become effective or any
subsequent supplement to the Prospectus, other than documents incorporated by reference, has been filed and of any request by the Commission for any amendment or supplement related to any Placement to the Registration Statement or Prospectus or for
additional information related to any Placement, (ii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus relating to the Placement Shares (except for documents incorporated by reference) unless a
copy thereof has been submitted to the Agent in a reasonable period of time before the filing and the Agent has reasonably objected thereto (provided, however, (A) that the failure of the Agent to make such objection shall not
relieve the Company of any
obligation or liability hereunder, or affect the Agents right to rely on the representations and warranties made by the Company in this Agreement and (B) that the Company has no
obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to object to such filing if such filing does not name the Agent or does not relate to the transactions contemplated hereunder) and the Company
will furnish to the Agent at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and
(iii) the Company will cause each amendment or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document to be
incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the time period prescribed. The determination to file or not file any amendment or supplement with the Commission under this
Section 7(a), based on the Companys reasonable opinion or reasonable objections, shall be made exclusively by the Company.
(b) Notice of Commission Stop Orders. During any period beginning with the Acceptance of a Placement Notice and ending
after a Prospectus relating to any Placement Shares is no longer required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act),
the Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, (i) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement; (ii) of the suspension
of the qualification of the Placement Shares for offering or sale in any jurisdiction; (iii) of the initiation of any proceeding for any of the purposes set out in (i) or (ii); or (iv) of any request by the Commission for any
amendments to the Registration Statement or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information related to
the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus. The Company will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be
issued.
(c) Delivery of Prospectus; Subsequent Changes. During any period in which a Prospectus relating to the
Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the
Securities Act), the Company will use its best efforts to comply with all requirements imposed upon it by each of the Securities Act and the Exchange Act, as from time to time in force, and to file on or before their respective due dates all reports
and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information
from the Registration Statement, pursuant to Rule 430A, it will use its best efforts to comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430A and to notify the Agent promptly of all
such filings. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent
to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such
compliance.
(d) Listing of Placement Shares. During any period in which the Prospectus relating to the Placement
Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities
Act), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such jurisdictions as the Agent reasonably designates
and to continue such qualifications in effect so long as required for the distribution of the Placement Shares; provided, however, that the Company shall not be required in connection therewith to qualify as a foreign corporation or
dealer in securities or file a general consent to service of process in any jurisdiction.
(e) Delivery of Registration Statement and Prospectus. The Company will
furnish to the Agent and its counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement or
Prospectus that are filed with the Commission during any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission during such period that
are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agents request, will also furnish copies of the
Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent such
document is available on EDGAR.
(f) Earnings Statement. The Company will make generally available to its security
holders as soon as practicable, but in any event not later than 15 months after the end of the Companys current fiscal quarter, an earnings statement covering a 12-month period that satisfies the
provisions of Section 11(a) and Rule 158 of the Securities Act.
(g) Expenses. The Company, whether or not
the transactions contemplated hereunder are consummated or this Agreement is terminated, in accordance with the provisions of Section 11 hereunder, will pay all expenses incident to the performance of its obligations hereunder relating to
(i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of each Prospectus and of each amendment and supplement thereto, (ii) the preparation, issuance and delivery of the Placement
Shares, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of Section 7(d) of this Agreement, including filing fees, (iv) the printing and delivery to the Agent of copies of the
Prospectus and any amendments or supplements thereto, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on the Exchange, (vi) filing fees and expenses, if any, of the
Commission and the FINRA Corporate Finance Department.
(h) Use of Proceeds. The Company will use the Net Proceeds
as described in the Prospectus in the section entitled Use of Proceeds.
(i) Notice of Other
Sales. During the pendency of any Placement Notice given hereunder, or any period in which the Prospectus relating to the Placement Shares is required to be delivered by the Agent, the Company shall provide the Agent notice as promptly as
reasonably possible before it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than Placement Shares offered pursuant to the provisions of this Agreement) or securities
convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire Common Stock; provided, that such notice shall not be required in connection with the issuance of shares of Common Stock upon exercise of
stock options and warrants disclosed as outstanding in the Registration Statement and the Prospectus, the grant of options under existing stock option plans described in the Registration Statement and the Prospectus, the issuance of Common Stock
pursuant to the Companys dividend reinvestment and stock purchase plans described in the Registration Statement and the Prospectus, or issuances pursuant to consulting arrangements or service provider arrangements the primary purpose of which
is not to raise capital, unless such arrangements are required to be disclosed on a Current Report on Form 8-K.
(j) Change of Circumstances. During the pendency of any Placement Notice given hereunder, or any period in which the
Prospectus relating to the Placement Shares is required to be delivered by the Agent, the Company will advise the Agent promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect
in any material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to Sections 7(l) and 7(n) of this Agreement.
(k) Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the
Agent or its agents in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Companys
principal offices, as the Agent may reasonably request.
(l) Required Filings Relating to Placement of Placement
Shares. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the
Commission under the applicable paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold
through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or
market on which such sales were effected as may be required by the rules or regulations of such exchange or market.
(m)
Representation Dates; Certificate. During the term of this Agreement, on the date of the first Placement Notice given hereunder and within seven days of each time the Company (i) amends the Registration Statement by means of a post-effective amendment or amends or supplements the Prospectus relating to the Placement Shares (other than by means of incorporation of document(s) by reference to the Registration Statement or the Prospectus);
(ii) files an annual report on Form 10-K under the Exchange Act; or (iii) files its quarterly reports on Form 10-Q under the Exchange Act (each date
of filing of one or more of the documents referred to in clauses (i) through (iii) shall be a Representation Date); the Company shall furnish the Agent with a certificate, in the form attached hereto as
Exhibit 7(m). The requirement to provide a certificate under this Section 7(m) shall be waived for any Representation Date occurring during a fiscal quarter during which the Company does not intend to sell Placement Shares prior to the
next occurring Representation Date; provided, however, that such waiver shall not apply for any Representation Date on which the Company files its annual report on Form 10-K. Notwithstanding
the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide the Agent with a certificate under this Section 7(m), then before the Agent
either delivers the Placement Notice or sells any Placement Shares, the Company shall provide the Agent with a certificate, in the form attached hereto as Exhibit 7(m), dated the date of the Placement Notice.
(n) Legal Opinion. On or prior to the delivery of the first Placement Notice given hereunder and within seven days of
the filing by the Company of an annual report on Form 10-K under the Exchange Act, the Company shall cause to be furnished to the Agent a written letter of Choate, Hall & Stewart LLP, in a form
reasonably acceptable to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In addition, in the event the Company materially amends or restates financial
information that was included or incorporated by reference in a filing with the Commission or otherwise engages in a significant acquisition or other material transaction which, in the reasonable judgment of the Agent, results in the disclosures of
the Company to be materially altered, then, at the Agents request, the Company shall cause to be furnished to the Agent a written letter of Company counsel, in form and substance reasonably acceptable to the Agent and its counsel, modified as
necessary to relate to the Registration Statement and the Prospectus as then amended or supplemented.
(o) Comfort
Letter. On or prior to the date of the first Placement Notice given hereunder and thereafter within seven days of the filing by the Company of an annual report on Form 10-K under the Exchange Act the
Company shall cause its independent accountants to furnish to the Agent a letter, dated as of such date, in a form reasonably acceptable to the Agent and its counsel, confirming that they are independent accountants within the meaning of the
Securities Act and the Exchange Act and the respective applicable published rules and regulations thereunder, including without limitation the rules of the Public Company Accounting Oversight Board and
Rule 2-01 of Regulation S-X, and that:
(i) in their opinion the audited financial statements and financial statement schedules included or incorporated in the
Registration Statement and the Prospectus and audited by them comply as to form in all material respects with the applicable accounting requirements of the Securities Act and the Exchange Act and the related published rules and regulations;
(ii) nothing has came to their attention which caused them to believe that the information included in the Registration
Statement and the Prospectus in response to Regulation S-K, Item 301 (Selected Financial Data), Item 302 (Supplementary Financial Information) and Item 503(d) (Ratio of Earnings to Fixed
Charges) is not in conformity with the applicable disclosure requirements of Regulation S-K; and
(iii) they have performed certain other specified procedures as a result of which they determined that certain information of
an accounting, financial or statistical nature (which is limited to accounting,
financial or statistical information derived from the general accounting records of the Company and its subsidiaries) set forth in the Registration Statement and the Prospectus, including the
information included or incorporated in Items 1, 2, 6, 7, 7A, 11 and 13 of the Companys Annual Report on Form 10-K, incorporated in the Registration Statement and the Prospectus, and the
information included in the Managements Discussion and Analysis of Financial Condition and Results of Operations included in each of the Companys Quarterly Reports on
Form 10-Q, incorporated in the Registration Statement and the Prospectus, agrees with the accounting records of the Company and its subsidiaries, excluding any questions of legal interpretation.
References to the Prospectus in this paragraph include any supplement thereto at the date of the letter.
(p) Market Activities. The Company will not, directly or indirectly take any action designed to cause or result in, or
that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares.
8. Conditions to the Agents Obligations. The obligations of the Agent hereunder with respect to a Placement will be subject to
the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to
the Agent in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion with such waiver for a given Placement having no effect on any other Placement) of the following additional conditions:
(a) Registration Statement Effective. The Registration Statement shall have become effective and shall be available for
the sale of all Placement Shares contemplated to be issued by any Placement Notice.
(b) No Material Notices. None
of the following events shall have occurred and be continuing: (i) receipt by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of
the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any
other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to
the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; (iv) the occurrence of any event that makes any
material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the
Registration Statement, related Prospectus or documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
(c) No Misstatement or Material
Omission. The Agent shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agents reasonable opinion is material, or omits
to state a fact that in the Agents opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.
(d) Material Changes. Except as contemplated in the Prospectus, or disclosed in the Companys reports filed with
the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material
Adverse Effect, or a downgrading in or withdrawal of the rating assigned to any of the Companys securities (other than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under
surveillance or review its rating of any of the Companys securities (other than asset backed securities), the effect of which, in the
case of any such action by a rating organization described above, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is
so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.
(e) Legal Opinion. The Agent shall have received the opinions and letters required to be delivered pursuant
Section 7(n) on or before the date on which such delivery of such opinions or letters are required pursuant to Section 7(n).
(f) Comfort Letter. The Agent shall have received the Comfort Letter required to be delivered pursuant Section 7(o)
on or before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(o).
(g)
Representation Certificate. The Agent shall have received the certificate required to be delivered pursuant to Section 7(m) on or before the date on which delivery of such certificate is required pursuant to Section 7(m).
(h) No Suspension. Trading in the Common Stock shall not have been suspended on the Exchange.
(i) Other Materials. On the date hereof and on each date on which the Company is required to deliver a certificate
pursuant to Section 7(m), the Company shall use its commercially reasonable efforts to furnish to the Agent such appropriate further information, certificates and documents as the Agent may reasonably request. All such opinions, certificates,
letters and other documents will be in compliance with the provisions hereof. The Company will furnish the Agent with such conformed copies of such opinions, certificates, letters and other documents as the Agent shall reasonably request.
(j) Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to
have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.
(k) Approval for Listing. The Placement Shares shall either have been (i) approved for listing on the Exchange,
subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance of any Placement Notice.
(l) No Termination Event. There shall not have occurred any event that would permit the Agent to terminate this
Agreement pursuant to Section 11(a).
9. Indemnification and Contribution.
(a) Indemnification by the Company. The Company agrees to indemnify and hold harmless the Agent and its directors,
officers, partners, employees and agents and each person, if any, who (i) controls the Agent within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, or (ii) is controlled by or is under common
control with the Agent from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any
action, suit or proceeding or any claim asserted), as and when incurred, to which the Agent, or any such person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, or at common law or
otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or
the Prospectus or any amendment or supplement to the Registration Statement or the Prospectus, or in any Issuer Free-Writing Prospectus, or (y) the omission or alleged omission to state in such document a
material fact required to be stated in it or necessary to make the statements in it not misleading; provided, however, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage
arises from the sale of the Placement Shares pursuant to this Agreement and is caused directly or indirectly by an untrue statement or omission, or alleged untrue statement or omission, made in reliance on and in conformity with information relating
to the Agent and furnished in writing to the Company by or on behalf of the Agent expressly for inclusion in any document described in clause (a)(x) above. This indemnity agreement will be in addition to any liability that the Company might
otherwise have.
(b) Indemnification by the Agent. The Agent agrees to indemnify and hold
harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act or (ii) is controlled by or is under common control with the Company (a Company Affiliate) against any and all losses, liabilities, claims, damages and expenses to which the Company, or any Company
Affiliate, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, as and when incurred, but only insofar as such losses, claims, liabilities, expenses or
damages arise out of or are based, directly or indirectly, on untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement or the Prospectus or any amendment or supplement to the Registration
Statement or the Prospectus, or in any Issuer Free-Writing Prospectus in reliance upon and in conformity with written information relating to the Agent and furnished to the Company by or on behalf of the Agent
expressly for inclusion in any document as described in Section 9(a). The Company acknowledges that, for all purposes under this Agreement, the name of the Agent and the paragraph relating to placement agent fees and reimbursement of expenses
appearing in the Prospectus constitute the only information relating to the Agent furnished in writing to the Company by the Agent expressly for inclusion in the Registration Statement or the Prospectus.
(c) Procedure. Any party that proposes to assert the right to be indemnified under this Section 9 will, promptly
after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnified party or parties under this Section 9, notify each such indemnifying party of the commencement of such
action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this
Section 9 and (ii) any liability that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such omission results in the forfeiture or material impairment of
substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the
extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the
defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the
indemnified party for any legal or other expenses except as provided below. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of
such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, or (2) the indemnifying party has not in fact employed counsel to assume the defense of such
action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is
understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm
admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party
will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry
of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent includes an
unconditional release of each indemnified party from all liability arising or that may arise out of such claim, action or proceeding.
(d) Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification
provided for in the foregoing paragraphs of this Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or the Agent, the Company and the Agent will contribute to the total losses,
claims, liabilities, expenses and damages (including any
investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted but after deducting any
contribution received by the Company from persons other than the Agent such as persons who control the Company within the meaning of the Securities Act or the Exchange Act, officers of the Company who signed the Registration Statement and directors
of the Company, who also may be liable for contribution) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received. The relative benefits received shall be deemed to be in
the same proportion as the total net proceeds from the sale of the Placement Shares (net of commissions to the Agent but before deducting expenses) received by the Company as set forth on the cover of the Prospectus bear to the total compensation
received by the Agent from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other, with respect to the statements or omission that resulted in
such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to
information and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this Section 9(d) were to be determined by pro rata allocation or
by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect
thereof, referred to above in this Section 9(d) shall be deemed to include, for the purpose of this Section 9(d), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any
such action or claim to the extent consistent with Section 9(c) hereof. Notwithstanding the foregoing provisions of this Section 9(d), the Agent shall not be required to contribute any amount in excess of the commissions received by it
under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 9(d), any person who controls a party to this Agreement within the meaning of the Securities Act or the Exchange Act, and any officers, directors, partners, employees or agents of the Agent, will
have the same rights to contribution as that party, and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to
contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9(d), will notify any such party or parties from whom contribution may
be sought, but the omission so to notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section 9(d) except to the extent that the failure to so notify such
other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 9(c) hereof, no party will be liable for
contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section 9(c) hereof.
10. Representations and Agreements to Survive Delivery. All representations and warranties of the Company herein or in certificates
delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of their respective officers, directors or controlling
persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.
11. Termination.
(a) The Agent shall have the right by giving notice as hereinafter specified at any time to terminate this Agreement if
(i) any Material Adverse Effect, or any development that has actually occurred and that is reasonably expected to cause a Material Adverse Effect has occurred that, in the reasonable judgment of the
Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part
to be performed hereunder; provided, however, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion, or letter required under Sections 7(m), 7(n), or 7(o), the Agents
right to terminate shall not arise unless (A) such failure to deliver (or cause to be delivered) continues for more than thirty days from the date such delivery was required; and (B) the Agent has not waived such requirement; and
(C) the Company has not completed performance prior to Agents communication to the Company of Agents intent to terminate; or (iii) any other condition of Agents obligations hereunder is not fulfilled, or (iv), any
suspension or limitation of trading in the Placement Shares or in securities generally on the Exchange shall have occurred. Any such termination shall be without liability of any party to any other party except that the provisions of
Section 7(g) (Expenses), Section 9 (Indemnification), Section 10 (Representations and Agreements to Survive Delivery), Section 16 (Applicable Law; Consent to Jurisdiction) and Section 17(Waiver of Jury Trial) hereof shall
remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section 11(a), Agent shall provide the required notice as specified in Section 12 (Notices).
(b) The Company shall have the right, by giving ten days notice as hereinafter specified to terminate this Agreement in its
sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 16 and
Section 17 hereof shall remain in full force and effect notwithstanding such termination.
(c) The Agent shall have
the right, by giving ten days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.
(d) Unless earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance
and sale of all of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; provided that the provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17
hereof shall remain in full force and effect notwithstanding such termination.
(e) This Agreement shall remain in full
force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed
to provide that Section 7(g), Section 9, Section 10, Section 16 and Section 17 shall remain in full force and effect.
(f) Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided,
however, that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale
of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.
12. Notices. All
notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing and (a) if sent to the Agent, shall be delivered to: (i) MLV & Co. LLC,
1251 Avenue of the Americas, 41st Floor, New York, NY 10020, Attention: Patrice McNicoll, Facsimile: (646) 417-7205, Email: PMcNicoll@mlvco.com;
and with a copy to (ii) LeClairRyan, A Professional Corporation, 885 Third Avenue, Sixteenth Floor, New York, NY 10022, Attention: James T. Seery, Esq., Facsimile: (973) 986-3509, Email:
james.seery@leclairryan.com; or (b) if sent to the Company, shall be delivered to Agenus Inc., 149 Fifth Ave, Suite 500, NY 10010, attention: Garo H. Armen, Chief Executive Officer, Facsimile: (212) 994-8299, Email: armen@agenusbio.com,
with copies Agenus Inc., 3 Forbes Road, Lexington, MA 02421 attention: Legal Department, Facsimile: 781-674-4200, Email: karen.valentine@agenusbio.com and to Choate,
Hall & Stewart LLP, Two International Place, Boston, MA 02110, Attention: Gerald E. Quirk, Esq., Facsimile: 617-248-4000, Email: gquirk@choate.com. Each party to this Agreement may change such address for notices by sending to the parties
to this Agreement written notice of
a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally, by email or by verifiable facsimile transmission (with an
original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of
this Agreement, Business Day shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.
13. Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their
respective successors and the affiliates, controlling persons, officers and directors referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns
of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party.
14. Adjustments for Stock Splits. The parties acknowledge and agree that all share-related
numbers contained in this Agreement shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Common Stock.
15. Entire Agreement; Amendment; Severability. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof, including the
Original Sales Agreement. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the provisions contained herein, or the
application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and
enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the
remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.
16.
Applicable Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably
submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any
transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is
brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by
mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
17. Waiver of Jury Trial. The Company and the Agent each hereby irrevocably waives any right it may have to a trial by jury in respect
of any claim based upon or arising out of this agreement or any transaction contemplated hereby.
18. Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile
transmission.
If the foregoing correctly sets forth the understanding between the Company and MLV, please so
indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and MLV.
Very truly
yours,
|
|
|
|
|
AGENUS INC. |
|
|
By: |
|
/s/ Garo H. Armen |
|
|
|
|
|
|
|
Title: |
|
Chief Executive Officer |
ACCEPTED as of the date first-above written
|
|
|
|
|
MLV & CO. LLC |
|
|
By: |
|
/s/ Dean M. Colucci |
SCHEDULE 1
FORM OF PLACEMENT NOTICE
|
|
|
From: |
|
MLV & Co. LLC
Attention: Patrice McNicoll |
To: |
|
Agenus Inc.
Subject: At Market
IssuancePlacement Notice |
Ladies and Gentlemen:
Pursuant to the terms and subject to the conditions contained in the At Market Issuance Sales Agreement between Agenus Inc., a Delaware
corporation (the Company), and MLV & Co. LLC, a Delaware limited liability company (MLV), dated October 10, 2014, the Company has requested that MLV sell up to
shares of the Companys common stock, par value $0.01 per share (Common Stock), at a minimum market price of
$ per share, during the time period beginning [month, day, time] and ending [month, day, time] (the Expiration Time).
By accepting the terms of this Placement Notice, the Company confirms that the Company meets the eligibility requirements of General
Instruction I.B.1 of Form S-3.
|
|
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
|
Title: |
|
[Chief Executive Officer] |
|
|
[VP, Finance] |
Date:
SCHEDULE 2
Compensation
The Company shall pay to MLV in
cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to up to 3.0% of the gross proceeds from each sale of Placement Shares.
SCHEDULE 3
Notice Parties
The Company:
Garo Armen
The Agent:
Randy Billhardt
Dean Colucci
Ryan Loforte
Patrice McNicoll
Miranda Toledano
EXHIBIT 7(m)
Form of Representation Date Certificate
This Officers Certificate (this Certificate) is executed and delivered in connection with Section 7(m) of the At
Market Issuance Sales Agreement (the Agreement), dated October 10, 2014, and entered into between Agenus Inc. (the Company) and MLV & Co. LLC. All capitalized terms used but not defined herein
shall have the meanings given to such terms in the Agreement
The undersigned has carefully examined the Registration Statement, the
Prospectus, any supplements to the Prospectus (each as defined in the Agreement) and the Agreement and hereby certifies that:
1. As of the
date of this Certificate, (i) the Registration Statement does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading
and (ii) neither the Registration Statement nor the Prospectus contains any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein not untrue or misleading.
2. Each of the representations and warranties of the Company contained in the Agreement was true and correct in all material respects, when
originally made, and, except for those representations and warranties that speak solely as of a specific date, is true and correct as of the date of this Certificate.
3. Except as waived by MLV in writing, each of the covenants required to be performed by the Company in the Agreement on or prior to the date
of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement, has been performed in all material respects and each condition required to be complied with by the Company on or prior to
the date of the Agreement, this Representation Date, and each such other date prior to the date hereof as set forth in the Agreement has been complied with in all material respects.
4. Subsequent to the date of the most recent financial statements in the Prospectus, and except as described in the Prospectus, there has been
no Material Adverse Effect.
5. No stop order suspending (a) the effectiveness of the Registration Statement or of any part thereof
or (b) the qualification or registration of the Placement Shares under the securities or Blue Sky laws of any jurisdiction has been issued, and, to the Companys knowledge, no proceedings for that purpose have been instituted or are
pending or threatened by any securities or other governmental authority (including, without limitation, the Commission).
Exhibit 5.1
October 10, 2014
Agenus Inc.
3 Forbes Road
Lexington, MA 02421
Ladies and Gentlemen:
This opinion is furnished
to you in connection with the Registration Statement on Form S-3 (as amended from time to time, and including the prospectuses contained therein and any prospectus supplement thereto, the Registration Statement) being filed by
Agenus Inc., a Delaware corporation (the Company), with the Securities and Exchange Commission (the Commission) under the Securities Act of 1933, as amended (the Securities Act), with respect
to the following securities of the Company covered in a primary base offering, all of which may be issued from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act at a proposed aggregate maximum offering
price not to exceed $150,000,000:
|
(i) |
common stock, $0.01 par value per share (Common Stock); |
|
(ii) |
preferred stock, $0.01 par value per share (Preferred Stock); |
|
(iii) |
warrants to purchase shares of common stock, preferred stock and/or debt securities (the Warrants); |
|
(iv) |
debt securities consisting of debentures, notes, or other evidences of indebtedness (Debt Securities); and |
|
(v) |
units consisting of any combination of the foregoing securities (the Units). |
In addition to the foregoing, there are being registered under the Registration Statement 10,000,000 shares of Common Stock that may be issued
and sold under the At Market Issuance Sales Agreement (the Sales Agreement), dated as of the date hereof, between the Company and MLV & Co. LLC.
The Common Stock, Preferred Stock, Warrants, Debt Securities and Units are hereinafter collectively referred to as the
Securities. The Securities may be issued and sold or delivered from time to time as set forth in the Registration Statement, any amendment thereto, the prospectuses contained therein and any supplements thereto.
The Securities may be issued pursuant to the Sales Agreement and one or more additional underwriting agreements, purchase agreements,
subscription agreements or similar agreements between the Company and the underwriters or purchasers to be named in such later agreements (collectively, the Purchase Agreements).
The Debt Securities may be issued pursuant to an indenture between the Company and a trustee to be named in such indenture (the
Indenture).
We have examined, and are familiar with, and have relied as to factual matters solely upon, the
Registration Statement, the Companys Amended and Restated Certificate of Incorporation, the amended and restated by-laws of the Company, the minute books of the Company and originals of such other documents, certificates and proceedings as we
have deemed necessary for the purpose of rendering this opinion. In our examination of documents, we have assumed the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to
us as conformed or copies, the genuineness of all signatures, the legal capacity of all natural persons, and the completeness and accuracy of the corporate records of the Company provided to us. Insofar as this opinion relates to factual matters, we
have assumed with your permission and without independent investigation that the statements of the Company contained in the Registration Statement are true and correct as to all factual matters stated therein.
Agenus Inc.
October 10, 2014
Page 2
We have relied as to certain matters on information obtained from public officials, officers
of the Company, and other sources believed by us to be reliable and we have assumed that any Purchase Agreements, Indenture and other agreements related to the Securities or their offer, sale, issuance and resale (the Related
Agreements) will be duly authorized, executed and delivered by all parties thereto other than the Company, assumptions which we have not independently verified. We are expressing no opinion herein as to the application of any federal or
state law or regulation to the power, authority or competence of any party to a Purchase Agreement, an Indenture or any Related Agreements other than the Company. We have assumed that such agreements will be the valid and binding obligations of each
party thereto other than the Company, and enforceable against each such other party in accordance with their respective terms.
We express
no opinion with respect to the applicability of any law other than the state laws of the state of Delaware (without giving effect to conflicts of law principles).
Our opinions set forth below are qualified to the extent that they may be subject to or affected by (a) applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws relating to or affecting the rights of creditors generally, (b) statutory or decisional law concerning recourse by creditors to security in the absence of notice or
hearing, (c) duties and standards imposed on creditors and parties to contracts, including, without limitation, requirements of good faith, reasonableness and fair dealing and (d) general equitable principles. We express no opinion as to
the availability of any equitable or specific remedy upon any breach of any of the agreements as to which we are opining herein, or any of the agreements, documents or obligations referred to therein, or to the successful assertion of any equitable
defenses, inasmuch as the availability of such remedies or the success of any such defenses may be subject to the discretion of a court.
We also express no opinion herein as to any provision of any agreement (a) which may be deemed to or construed to waive any right of the
Company, (b) to the effect that rights and remedies are not exclusive, that every right or remedy is cumulative and may be exercised in addition to or with any other right or remedy and does not preclude recourse to one or more other rights or
remedies, (c) relating to the effect of invalidity or unenforceability of any provision of any agreement on the validity or enforceability of any other provision thereof, (d) requiring the payment of penalties, consequential damages or
liquidated damages, (e) purporting to indemnify any person against his, her or its own negligence or intentional misconduct, (f) any provision of any agreement requiring the payment of interest on overdue interest, (g) which provides
that the terms of any agreement may not be waived or modified except in writing or (h) relating to choice of law or consent to jurisdiction.
Based upon and subject to the foregoing, we are of the opinion that:
1. When the terms of the issuance and sale of the Common Stock or Preferred Stock, have been duly authorized by the Company,
the designation, preferences, limitations and relative rights of the Preferred Stock have been established in accordance with the Companys Amended and Restated Certificate of Incorporation, and the Common Stock or Preferred Stock has been duly
issued and sold against payment of the purchase price therefor and issued and sold as contemplated in the Registration Statement and any applicable prospectus or prospectus supplement relating thereto, the Common Stock or Preferred Stock will be
validly issued, fully paid and non-assessable.
2. When the terms of the Warrants and of their issuance and sale have been
duly authorized by the Company, the applicable warrant agreement has been duly authorized, executed and delivered by the parties thereto and such Warrants have been duly executed and delivered in accordance with the applicable warrant agreement and
issued and sold against payment of the purchase price therefor and issued and sold as contemplated in the Registration Statement and any applicable prospectus or prospectus supplement relating thereto, such Warrants will constitute valid and binding
obligations of the Company.
Agenus Inc.
October 10, 2014
Page 3
3. When the terms of the Debt Securities and of their issuance and sale have
been duly authorized by the Company and duly established in conformity with the Indenture, and the Debt Securities have been duly executed, authenticated and delivered in accordance with the Indenture against payment of the purchase price therefor,
and issued and sold as contemplated in the Registration Statement and any applicable prospectus or prospectus supplement relating thereto, the Debt Securities will constitute valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms.
4. When the terms of the Units and of their issuance and sale have been duly
authorized by the Company, the applicable Units have been duly authorized, executed and delivered by the parties thereto and such Units have been duly executed and delivered and issued and sold against payment of the purchase price therefor and
issued and sold as contemplated in the Registration Statement and any applicable prospectus or prospectus supplement relating thereto, such Units will constitute valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms.
In rendering the opinions set forth above, we have assumed (i) that the Registration Statement will
have become effective under the Securities Act, and, with respect to Securities other than Common Stock sold pursuant to the Sales Agreement, that a prospectus supplement will have been prepared and filed with the Commission describing the
Securities offered thereby; and (ii) the Company will have reserved a sufficient number of shares of its duly authorized, but unissued, Common Stock and Preferred Stock as is necessary to provide for any issuance of the shares of Common Stock
and Preferred Stock pursuant to the Registration Statement.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the
Registration Statement and to the use of our name in the Registration Statement under the caption Legal Matters in the prospectuses included as a part thereof. In giving this consent, we do not admit that we are in the category of
persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.
This opinion is limited to the Delaware General Corporation Law (which includes applicable provisions of the Delaware Constitution and
reported judicial decisions interpreting the Delaware General Corporation Law and the Delaware Constitution), the laws of The Commonwealth of Massachusetts and the federal laws of the United States of America. It is understood that this opinion is
to be used only in connection with the offer and sale of the Securities while the Registration Statement is in effect and may not be used, quoted or relied upon for any other purpose. This opinion is limited to the matters expressly set forth
herein. We express no opinion as to the application of or compliance with the securities and Blue Sky laws of any state or the antifraud provisions of any federal or state securities laws. This opinion is given and speaks only as of the date hereof
and is limited to our knowledge of the facts and the laws, statutes, rules and regulations, and judicial and administrative interpretations thereof, as currently in effect, and assumes no event will take place in the future which will affect the
opinions set forth herein. These are all subject to change, possibly with retroactive effect. We assume no obligation to advise any party of changes of any kind that may hereafter be brought to our attention, even if such changes would affect our
opinion, or to update or supplement this opinion after the date hereof.
Very truly yours,
/s/ CHOATE, HALL AND STEWART LLP
Exhibit 12.1
Statement Regarding Computation of Ratios of Earnings to Fixed Charges
and Earnings to Combined Fixed Charges and Preferred Stock Dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Calculation of Ratio of Earnings to Fixed Charges |
|
|
|
Six Months Ended June 30, |
|
|
For the Year Ended December 31, |
|
|
|
2014 |
|
|
2013 |
|
|
2012 |
|
|
2011 |
|
|
2010 |
|
|
2009 |
|
Ratio of Earnings to Fixed Charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income taxes |
|
$ |
(8,399 |
) |
|
$ |
(30,073 |
) |
|
$ |
(11,325 |
) |
|
$ |
(23,276 |
) |
|
$ |
(21,906 |
) |
|
$ |
(30,318 |
) |
Add : Fixed charges per below |
|
|
924 |
|
|
|
2,948 |
|
|
|
5,053 |
|
|
|
4,780 |
|
|
|
5,741 |
|
|
|
6,297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss, as adjusted |
|
|
(7,475 |
) |
|
|
(27,125 |
) |
|
|
(6,272 |
) |
|
|
(18,496 |
) |
|
|
(16,165 |
) |
|
|
(24,021 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense on indebtedness |
|
|
674 |
|
|
|
2,428 |
|
|
|
4,718 |
|
|
|
4,210 |
|
|
|
4,871 |
|
|
|
5,345 |
|
Estimated interest expense within rental expense |
|
|
250 |
|
|
|
520 |
|
|
|
335 |
|
|
|
570 |
|
|
|
870 |
|
|
|
952 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total fixed charges |
|
|
924 |
|
|
|
2,948 |
|
|
|
5,053 |
|
|
|
4,780 |
|
|
|
5,741 |
|
|
|
6,297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of earnings to cover fixed charges |
|
$ |
(8,399 |
) |
|
$ |
(30,073 |
) |
|
$ |
(11,325 |
) |
|
$ |
(23,276 |
) |
|
$ |
(21,906 |
) |
|
$ |
(30,318 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss, as adjusted |
|
$ |
(7,475 |
) |
|
$ |
(27,125 |
) |
|
$ |
(6,272 |
) |
|
$ |
(18,496 |
) |
|
$ |
(16,165 |
) |
|
$ |
(24,021 |
) |
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense on indebtedness |
|
|
674 |
|
|
|
2,428 |
|
|
|
4,718 |
|
|
|
4,210 |
|
|
|
4,871 |
|
|
|
5,345 |
|
Estimated interest expense within rental expense |
|
|
250 |
|
|
|
520 |
|
|
|
335 |
|
|
|
570 |
|
|
|
870 |
|
|
|
952 |
|
Dividends on preferred stock |
|
|
102 |
|
|
|
3,160 |
|
|
|
792 |
|
|
|
790 |
|
|
|
790 |
|
|
|
790 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total fixed charges and preferred stock dividends |
|
|
1,026 |
|
|
|
6,108 |
|
|
|
5,845 |
|
|
|
5,570 |
|
|
|
6,531 |
|
|
|
7,087 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of earnings to cover combined fixed charges and preferred stock dividends |
|
$ |
(8,501 |
) |
|
$ |
(33,233 |
) |
|
$ |
(12,117 |
) |
|
$ |
(24,066 |
) |
|
$ |
(22,696 |
) |
|
$ |
(31,108 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Agenus Inc.:
We consent to the use of our reports dated March 7, 2014, with respect to the consolidated balance sheets of Agenus Inc. and subsidiaries as of
December 31, 2013 and 2012, and the related consolidated statements of operations, stockholders equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2013, and the effectiveness of
internal control over financial reporting as of December 31, 2013, incorporated herein by reference and to the reference to our firm under the heading Experts in the prospectus.
/s/ KPMG LLP
Boston,
Massachusetts
October 10, 2014
Exhibit 23.3
Consent of Independent Auditors
We
consent to the reference to our firm under the caption Experts in the Registration Statement (Form S-3) and related Prospectuses of Agenus Inc. for the registration of up to $ 150,000,000 of common stock, preferred stock, warrants, debt
securities and units of Agenus Inc. and the incorporation by reference therein of our report dated March 12, 2014 with respect to the financial statement of 4-Antibody AG for the year ended December 31, 2013 included in the Current Report
on Form 8-K of Agenus Inc. filed with the Securities and Exchange Commission on February 13, 2014 as amended by the Current Report on Form 8-K/A filed on April 29, 2014.
/s/ Ernst & Young Ltd.
Basel, Switzerland
October 10, 2014
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024